<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">C4JcmvSTDKXyCxSbgCQCTcp</article-id>
      <article-id pub-id-type="other">00011</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2009001000011</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(09)09300411</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2009001000011</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>O eletrocardiograma no diagn&#243;stico da hipertrofia ventricular de pacientes com doen&#231;a renal cr&#244;nica</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Costa</surname>
            <given-names>Francisco de Assis</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rivera</surname>
            <given-names>Ivan Romero</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Vasconcelos</surname>
            <given-names>Mirian Lira Castro de</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Costa</surname>
            <given-names>Andr&#233; Falc&#227;o Pedrosa</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>P&#243;voa</surname>
            <given-names>Rui Manoel dos Santos</given-names>
          </name>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bombig</surname>
            <given-names>Maria Tereza Nogueira</given-names>
          </name>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Luna Filho</surname>
            <given-names>Br&#225;ulio</given-names>
          </name>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lima</surname>
            <given-names>Valter Correia de</given-names>
          </name>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
      </contrib-group>
      <aff id="aff02">
        <addr-line>
          <named-content content-type="city">S&#227;o Paulo</named-content>
          <named-content content-type="state">S&#227;o Paulo</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade Federal de S&#227;o Paulo</institution>
        <institution content-type="orgdiv1">Escola Paulista de Medicina </institution>
        <country country="BR">Brazil</country>
      </aff>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">Macei&#243;</named-content>
          <named-content content-type="state">AL</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade Estadual de Ci&#234;ncias da Sa&#250;de de Alagoas</institution>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>10</month>
        <year>2009</year>
      </pub-date>
      <volume>93</volume>
      <issue>4</issue>
      <fpage>380</fpage>
      <lpage>386</lpage>
      <history>
        <date date-type="received">
          <day>25</day>
          <month>08</month>
          <year>2008</year>
        </date>
        <date date-type="rev-recd">
          <day>31</day>
          <month>10</month>
          <year>2008</year>
        </date>
        <date date-type="accepted">
          <day>31</day>
          <month>10</month>
          <year>2008</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>FUNDAMENTO: A hipertrofia ventricular esquerda (HVE) &#233; um fator preditor independente de risco cardiovascular e sua caracteriza&#231;&#227;o e preval&#234;ncia na doen&#231;a renal cr&#244;nica (DRC) carecem de melhor estudo. OBJETIVO: Estabelecer o diagn&#243;stico de HVE em pacientes com DRC em est&#225;gio 5 por seis diferentes crit&#233;rios eletrocardiogr&#225;ficos, correlacionando-os com o &#237;ndice de massa do ventr&#237;culo esquerdo (IMVE) obtido pelo ecocardiograma. M&#201;TODOS: Estudo transversal que incluiu 100 pacientes (58 homens e 42 mulheres, idade de 46,2 &#177; 14,0 anos) com DRC de todas as etiologias, h&#225; pelo menos seis meses em hemodi&#225;lise (HD). Foram obtidos eletrocardiograma (ECG) e ecocardiograma dos pacientes, sempre at&#233; uma hora ap&#243;s o t&#233;rmino das sess&#245;es de HD. RESULTADOS: A HVE foi detectada em 83 pacientes (83%), dos quais 56 (67,4%) apresentavam o padr&#227;o conc&#234;ntrico e 27 (32,6%) o padr&#227;o exc&#234;ntrico de HVE. Todos os m&#233;todos eletrocardiogr&#225;ficos estudados tiveram sensibilidade, especificidade e acur&#225;cia diagn&#243;sticas acima de 50%. Pela correla&#231;&#227;o linear de Pearson com o IMVE, apenas o crit&#233;rio de Sokolow-Lyon voltagem n&#227;o apresentou coeficiente &gt; 0,50. J&#225; o c&#225;lculo da raz&#227;o de verossimilhan&#231;a mostrou que o ECG possui poder discriminat&#243;rio para diagn&#243;stico de HVE na popula&#231;&#227;o estudada, com &#234;nfase para os crit&#233;rios de Cornell produto e Romhilt-Estes. N&#227;o houve correla&#231;&#227;o entre IMVE com o QTc e sua dispers&#227;o. CONCLUS&#195;O: O ECG &#233; um m&#233;todo &#250;til, eficaz e de alta reprodutibilidade no diagn&#243;stico de HVE dos pacientes em HD. Nessa popula&#231;&#227;o, o crit&#233;rio de Cornell produto mostrou-se o mais fidedigno para a detec&#231;&#227;o de HVE.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Nefropatias</kwd>
        <kwd>ecocardiografia</kwd>
        <kwd>eletrocardiografia</kwd>
        <kwd>hemodi&#225;lise</kwd>
        <kwd>hipertrofia ventricular esquerda</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>24</day>
        <month>11</month>
        <year>2009</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>ARTIGO ORIGINAL </p>
    <p> ELETROCARDIOGRAFIA</p>
    <p>
      <bold>O eletrocardiograma no diagn&#243;stico da hipertrofia ventricular de pacientes com doen&#231;a renal cr&#244;nica</bold>
    </p>
    <p>
      <bold>Francisco de Assis Costa<sup>I</sup>; Ivan Romero Rivera<sup>I</sup>; Mirian Lira Castro de Vasconcelos<sup>I</sup>; Andr&#233; Falc&#227;o Pedrosa Costa<sup>I</sup>; Rui Manoel dos Santos P&#243;voa<sup>II</sup>; Maria Tereza Nogueira Bombig<sup>II</sup>; Br&#225;ulio Luna Filho<sup>II</sup>; Valter Correia de Lima<sup>II</sup></bold>
    </p>
    <p><sup>I</sup>Universidade Estadual de Ci&#234;ncias da Sa&#250;de de Alagoas-UNCISAL, Macei&#243;, AL </p>
    <p><sup>II</sup>Universidade Federal de S&#227;o Paulo-Escola Paulista de Medicina-UNIFESP-EPM, S&#227;o Paulo, SP, Brasil</p>
    <p>
      <xref ref-type="corresp" rid="back">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p><bold>FUNDAMENTO: </bold> A hipertrofia ventricular esquerda (HVE) &#233; um fator preditor independente de risco cardiovascular e sua caracteriza&#231;&#227;o e preval&#234;ncia na doen&#231;a renal cr&#244;nica (DRC) carecem de melhor estudo. </p>
    <p><bold>OBJETIVO: </bold> Estabelecer o diagn&#243;stico de HVE em pacientes com DRC em est&#225;gio 5 por seis diferentes crit&#233;rios eletrocardiogr&#225;ficos, correlacionando-os com o &#237;ndice de massa do ventr&#237;culo esquerdo (IMVE) obtido pelo ecocardiograma. </p>
    <p><bold>M&#201;TODOS:</bold> Estudo transversal que incluiu 100 pacientes (58 homens e 42 mulheres, idade de 46,2 &#177; 14,0 anos) com DRC de todas as etiologias, h&#225; pelo menos seis meses em hemodi&#225;lise (HD). Foram obtidos eletrocardiograma (ECG) e ecocardiograma dos pacientes, sempre at&#233; uma hora ap&#243;s o t&#233;rmino das sess&#245;es de HD. </p>
    <p><bold>RESULTADOS: </bold> A HVE foi detectada em 83 pacientes (83%), dos quais 56 (67,4%) apresentavam o padr&#227;o conc&#234;ntrico e 27 (32,6%) o padr&#227;o exc&#234;ntrico de HVE. Todos os m&#233;todos eletrocardiogr&#225;ficos estudados tiveram sensibilidade, especificidade e acur&#225;cia diagn&#243;sticas acima de 50%. Pela correla&#231;&#227;o linear de Pearson com o IMVE, apenas o crit&#233;rio de Sokolow-Lyon voltagem n&#227;o apresentou coeficiente <underline>&gt;</underline> 0,50. J&#225; o c&#225;lculo da raz&#227;o de verossimilhan&#231;a mostrou que o ECG possui poder discriminat&#243;rio para diagn&#243;stico de HVE na popula&#231;&#227;o estudada, com &#234;nfase para os crit&#233;rios de Cornell produto e Romhilt-Estes. N&#227;o houve correla&#231;&#227;o entre IMVE com o QTc e sua dispers&#227;o. </p>
    <p><bold>CONCLUS&#195;O: </bold> O ECG &#233; um m&#233;todo &#250;til, eficaz e de alta reprodutibilidade no diagn&#243;stico de HVE dos pacientes em HD. Nessa popula&#231;&#227;o, o crit&#233;rio de Cornell produto mostrou-se o mais fidedigno para a detec&#231;&#227;o de HVE.</p>
    <p><bold>Palavras-chave: </bold> Nefropatias, ecocardiografia, eletrocardiografia, hemodi&#225;lise, hipertrofia ventricular esquerda.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>HVE &#233; um preditor independente de morbimortalidade na popula&#231;&#227;o geral quando diagnosticada, tanto pelo ECG, quanto pelo ecocardiograma<sup>1,2</sup>.</p>
    <p>Desde as observa&#231;&#245;es pioneiras do <italic>Framingham Heart Study</italic>, v&#225;rios estudos epidemiol&#243;gicos destacam a HVE como um dos mais importantes fatores de risco para angina do peito, infarto do mioc&#225;rdio, insufici&#234;ncia card&#237;aca, acidente vascular cerebral e morte s&#250;bita<sup>3</sup>.</p>
    <p>Na popula&#231;&#227;o de pacientes com DRC, em seus diversos est&#225;gios, as informa&#231;&#245;es dispon&#237;veis s&#227;o escassas. O estudo PREVEND analisou, pelo crit&#233;rio eletrocardiogr&#225;fico de Cornell produto, a presen&#231;a de HVE em indiv&#237;duos com disfun&#231;&#227;o renal, definida por taxa de filtra&#231;&#227;o glomerular (TFG) &lt; 60 ml/min/1,73 m<sup>2</sup> ou microalbumin&#250;ria, e encontrou preval&#234;ncia de 5,3%<sup>4</sup>. J&#225; estudos com ecocardiograma estimam entre 40% e 74% a preval&#234;ncia de HVE em pacientes com DRC em est&#225;gio 5, isto &#233;, aqueles com TFG &lt; 15 ml/min/1,73m<sup>2</sup> ou em terapia renal substitutiva<sup>5</sup>.</p>
    <p>A HVE pode ser detectada por ECG, radiografia de t&#243;rax, ecocardiograma e resson&#226;ncia nuclear magn&#233;tica. Entretanto, na pr&#225;tica cl&#237;nica, o ECG e o ecocardiograma s&#227;o os mais utilizados, n&#227;o apenas por raz&#245;es de disponibilidade, mas, sobretudo, pela rela&#231;&#227;o progn&#243;stica que prev&#234; claramente risco cardiovascular aumentado quando a HVE &#233; observada<sup>3</sup>.</p>
    <p>O principal objetivo do presente estudo &#233; estabelecer o diagn&#243;stico de HVE em pacientes com DRC em est&#225;gio 5, por seis diferentes crit&#233;rios eletrocardiogr&#225;ficos, correlacionando-os com o &#237;ndice de massa do ventr&#237;culo esquerdo (IMVE) diagnosticado pelo ecocardiograma.</p>
    <p>
      <bold>M&#233;todos</bold>
    </p>
    <p>
      <bold>Pacientes</bold>
    </p>
    <p>No per&#237;odo de junho de 2006 a fevereiro de 2007, foram avaliados, na Funda&#231;&#227;o Hospital da Agro-Ind&#250;stria do A&#231;&#250;car e do &#193;lcool de Alagoas, 133 pacientes portadores de DRC em est&#225;gio 5, de qualquer etiologia (ver <xref ref-type="table" rid="t1">tabela 1</xref>), clinicamente est&#225;veis, em programa de hemodi&#225;lise (HD) h&#225; pelo menos seis meses. O Comit&#234; de &#201;tica em Pesquisa em Seres Humanos da Universidade Estadual de Ci&#234;ncias da Sa&#250;de de Alagoas aprovou o protocolo de estudo e todos os pacientes assinaram o termo de consentimento livre e esclarecido, de acordo com os princ&#237;pios da Declara&#231;&#227;o de Helsinki. Foram os seguintes os crit&#233;rios de exclus&#227;o da pesquisa: antecedente de s&#237;ndrome coronariana aguda (independentemente do tempo) ou cr&#244;nica; doen&#231;a valvar; miocardiopatia de qualquer origem, detectada pelo ecocardiograma transtor&#225;cico; derrame peric&#225;rdico; portadores de marcapasso; bloqueio de ramo direito ou esquerdo; s&#237;ndromes de pr&#233;-excita&#231;&#227;o ventricular e qualquer outro ritmo que n&#227;o o sinusal. Ou seja, quaisquer fatores que potencialmente pudessem interferir com a an&#225;lise eletrocardiogr&#225;fica de HVE. Dos 133 pacientes rastreados, 33 foram exclu&#237;dos. Entre os 100 pacientes selecionados, todos foram entrevistados, quando era obtida a medida casual de press&#227;o arterial, e submetidos a ECG e a ecocardiograma transtor&#225;cico, sempre at&#233; uma hora ap&#243;s o t&#233;rmino das sess&#245;es de HD.</p>
    <table-wrap id="t1">
      <graphic xlink:href="1678-4170-abc-93-04-0380-00011-gt01.jpg"/></table-wrap>
    <p>
      <bold>Eletrocardiograma</bold>
    </p>
    <p>O ECG de repouso foi realizado com o paciente em posi&#231;&#227;o supina, obtendo-se as 12 deriva&#231;&#245;es, com velocidade de registro de 25 mm/s, calibra&#231;&#227;o padronizada para 1,0/ mV/cm (equipamento Dixtal, modelo EP3<sup>&#174;</sup>, Brasil). Os tra&#231;ados eletrocardiogr&#225;ficos foram analisados por um &#250;nico observador, cardiologista experiente, sem nenhum envolvimento com a realiza&#231;&#227;o dos ecocardiogramas, que executou todas as medidas manualmente, anotando-as da seguinte forma: amplitude (mm) da onda P; das ondas R de aV<sub>L</sub>, S de V<sub>3</sub>, S de V<sub>1</sub>, R de V<sub>5</sub> ou V<sub>6</sub> ;e maior onda R e S no plano horizontal; dura&#231;&#227;o (ms) da onda P, do complexo QRS, da ativa&#231;&#227;o ventricular, do intervalo QT corrigido pela f&#243;rmula de Bazzet (m&#233;dia das 12 deriva&#231;&#245;es) e da sua dispers&#227;o (QT m&#225;ximo - QT m&#237;nimo). Tamb&#233;m foram avaliados seis crit&#233;rios eletrocardiogr&#225;ficos para diagn&#243;stico de HVE: 1) Sokolow-Lyon voltagem (SV<sub>1</sub> + RV<sub>5</sub> ou V<sub>6</sub><underline>&gt;</underline> 35 mm)<sup>6</sup>; 2) Sokolow-Lyon produto (SV<sub>1</sub> + RV<sub>5</sub> ou V<sub>6</sub> X dura&#231;&#227;o de QRS <underline>&gt;</underline> 3000 mm.ms para mulheres e <underline>&gt;</underline> 4000 mm.ms para homens)<sup>7</sup>; 3) Cornell voltagem (RaV<sub>L</sub> + SV<sub>3</sub><underline>&gt;</underline> 20 mm para mulheres e <underline>&gt;</underline> 28 mm para homens)<sup>8</sup>; 4) Cornell produto (RaV<sub>L</sub> + SV<sub>3</sub> X dura&#231;&#227;o de QRS, para mulheres adicionar 6 mm, <underline>&gt;</underline> 2440 mm.ms)<sup>9</sup>; 5) Escore de pontos de Romhilt-Estes: maior amplitude de R ou S <underline>&gt;</underline> 30 mm no plano horizontal ou <underline>&gt;</underline> 20 mm no plano frontal ou padr&#227;o <italic>strain</italic> em V<sub>5</sub> ou V<sub>6</sub> (se em uso de digital vale apenas um ponto) ou crescimento do &#225;trio esquerdo pelo &#237;ndice de Morris (tr&#234;s pontos), eixo el&#233;trico de &#194;QRS acima de menos 30 graus (dois pontos), dura&#231;&#227;o de QRS <underline>&gt;</underline> 90 ms em V<sub>5</sub> ou V<sub>6</sub> ou tempo de ativa&#231;&#227;o ventricular <underline>&gt;</underline> 50 ms em V<sub>5</sub> ou V<sub>6</sub> (um ponto). Por esse escore, a HVE &#233; diagnosticada quando a soma de pontos &#233; <underline>&gt;</underline> 5<sup>10</sup>; 6) Escore de Per&#250;gia: a HVE &#233; diagnosticada pela presen&#231;a de um ou mais dos seguintes achados: crit&#233;rio de Cornell, considerando o limite para mulheres <underline>&gt;</underline> 20 mm e para homens <underline>&gt;</underline> 24 mm, escore de Romhilt-Estes e padr&#227;o <italic>strain</italic><sup>11</sup>. O estudo de reprodutibilidade do m&#233;todo foi feito pelo mesmo observador em ocasi&#245;es temporalmente distintas, de modo a n&#227;o ser capaz de recordar e identificar a primeira leitura, e por um observador independente, com doutorado em Cardiologia e grande experi&#234;ncia em eletrocardiografia, a partir da an&#225;lise de 30 tra&#231;ados apanhados aleatoriamente para avalia&#231;&#227;o das vari&#225;veis Sokolow-Lyon voltagem, Romhilt-Estes e intervalo QT.</p>
    <p>
      <bold>Ecocardiograma</bold>
    </p>
    <p>Os exames foram feitos por dois ecocardiografistas titulados pelo Departamento de Ecocardiografia da Sociedade Brasileira de Cardiologia, seguindo estritamente as normas preconizadas pela Diretriz para Indica&#231;&#245;es e Utiliza&#231;&#227;o da Ecocardiografia na Pr&#225;tica Cl&#237;nica<sup>12</sup>. Ressalte-se que nenhum desses dois observadores manteve qualquer rela&#231;&#227;o com a an&#225;lise dos tra&#231;ados de ECG. O paciente era posto em dec&#250;bito lateral esquerdo e utilizou-se o ecocardi&#243;grafo modelo Caris&#174; (Esaote-Biom&#233;dica, It&#225;lia), equipado com transdutor de 2,5/ MHz, procedendo-se aos cortes usuais para obten&#231;&#227;o de um estudo completo aos modos M, bidimensional e Doppler puls&#225;til; simultaneamente ao registro cont&#237;nuo do ECG. De acordo com as recomenda&#231;&#245;es da <italic>American Society of Echocardiography/European Association of Echocardiography</italic><sup>13</sup> as espessuras do septo interventricular (SIVD) e da parede posterior do ventr&#237;culo esquerdo (PPVED) foram obtidas em di&#225;stole, e a massa do VE, em grama, calculada segundo a f&#243;rmula: massa do VE = 0,8 X {1,04 [(SIVD + DDVE + PPVED)<sup>3</sup> - (DDVE)<sup>3</sup>]} + 0,6 g<sup>14</sup>, onde SIVD &#233; o septo interventricular em di&#225;stole, DDVE &#233; o di&#226;metro diast&#243;lico final do VE e PPVED &#233; a parede posterior do VE em di&#225;stole. A massa do VE foi corrigida para a superf&#237;cie corp&#243;rea. O diagn&#243;stico ecocardiogr&#225;fico de HVE foi firmado quando o IMVE foi &gt; 88 g/m<sup>2</sup> para mulheres e &gt; 102 g/m<sup>2</sup> para homens<sup>13</sup>. Foi calculada, tamb&#233;m, a espessura relativa da parede do VE (ERP) pela f&#243;rmula: ERP = 2 X PPVED/DDVE, onde PPVE &#233; a parede posterior do VE em di&#225;stole e DDVE &#233; o di&#226;metro diast&#243;lico final do VE. A partir do c&#225;lculo da ERP foi poss&#237;vel estabelecer os dois padr&#245;es geom&#233;tricos de HVE: conc&#234;ntrico, quando a ERP <underline>&gt;</underline> 0,42, e exc&#234;ntrico, quando ERP <underline>&lt;</underline> 0,42<sup>13</sup>. A fun&#231;&#227;o sist&#243;lica do VE foi avaliada pelo percentual de encurtamento da cavidade e pela fra&#231;&#227;o de eje&#231;&#227;o do VE obtida pelo m&#233;todo de Teicholz. A an&#225;lise de reprodutibilidade do m&#233;todo foi feita pelos mesmos ecorcardiografistas com 30 participantes, buscados aleatoriamente, que tiveram a massa do VE calculada pela f&#243;rmula de Devereux<sup>14</sup>. Um observador avaliava o mesmo exame em duas ocasi&#245;es temporalmente distintas, da mesma forma como na an&#225;lise eletrocardiogr&#225;fica. O outro observador realizava uma leitura do exame, sem conhecimento das leituras do primeiro observador.</p>
    <p>
      <bold>Medidas antropom&#233;tricas</bold>
    </p>
    <p>Foram verificados peso e altura, sempre at&#233; uma hora ap&#243;s o t&#233;rmino das sess&#245;es dial&#237;ticas. A superf&#237;cie corp&#243;rea, em m<sup>2</sup>, foi calculada conforme a equa&#231;&#227;o de Mosteller (0,20247 X peso<sup>0,425</sup> X altura<sup>0,725</sup>)<sup>15</sup>. O &#237;ndice de massa corp&#243;rea foi calculado pela divis&#227;o do peso (Kg) pelo quadrado da altura (m).</p>
    <p>
      <bold>An&#225;lise estat&#237;stica</bold>
    </p>
    <p>AS vari&#225;veis cont&#237;nuas foram expressas em m&#233;dia e desvio-padr&#227;o. As vari&#225;veis categ&#243;ricas foram expressas em percentagem. A associa&#231;&#227;o entre o IMVE e as demais vari&#225;veis de interesse foi feita por interm&#233;dio do coeficiente de correla&#231;&#227;o de Pearson. Para este estudo, considerou-se relevante apenas coeficiente de Pearson <underline>&gt;</underline> 0,50. Utilizou-se a curva ROC para estudo da sensibilidade, especificidade e acur&#225;cia dos seis crit&#233;rios eletrocardiogr&#225;ficos pesquisados, &#224; exce&#231;&#227;o do escore de Per&#250;gia (vari&#225;vel categ&#243;rica). O teste exato de Fisher foi utilizado para a compara&#231;&#227;o das sensibilidades dos m&#233;todos eletrocardiogr&#225;ficos avaliados, de acordo com os padr&#245;es geom&#233;tricos de HVE, e usou-se o teste t de Student para o cotejo entre o IMVE de homens e mulheres. A raz&#227;o de verossimilhan&#231;a (<italic>likelihood ratio)</italic> para os crit&#233;rios eletrocardiogr&#225;ficos foi tamb&#233;m calculada, utilizando-se para isso o coeficiente de concord&#226;ncia de Lin. Para a verifica&#231;&#227;o de signific&#226;ncia estat&#237;stica, em todas as compara&#231;&#245;es, foram considerados intervalos de confian&#231;a de 95% e p &lt; 0,05.</p>
    <p>
      <bold>Resultados</bold>
    </p>
    <p>Dos 100 pacientes que completaram o estudo, 58 eram homens (58%) e 42 eram mulheres (42%), com idade de 46,2 &#177; 14,0 anos (varia&#231;&#227;o de 18 a 78 anos) e tempo de HD de 50,7 &#177; 46,5 meses (varia&#231;&#227;o de seis a 225 meses, mediana de 33,5 meses). A <xref ref-type="table" rid="t2">tabela 2</xref> resume os dados demogr&#225;ficos e as caracter&#237;sticas cl&#237;nicas dos pacientes e a <xref ref-type="table" rid="t3">tabela 3</xref> re&#250;ne os achados eletrocardiogr&#225;ficos.</p>
    <table-wrap id="t2">
      <graphic xlink:href="1678-4170-abc-93-04-0380-00011-gt02.jpg"/></table-wrap>
    <table-wrap id="t3">
      <graphic xlink:href="1678-4170-abc-93-04-0380-00011-gt03.jpg"/></table-wrap>
    <p>A preval&#234;ncia de HVE pelo ecocardiograma foi de 83%, sendo que 56 destes pacientes (67,4%) apresentavam o tipo conc&#234;ntrico e 27 (32,6%) pacientes possu&#237;am o padr&#227;o exc&#234;ntrico de HVE. O IMVE na popula&#231;&#227;o estudada foi de 154,9 &#177; 57,3 g/m<sup>2</sup>. Separando-se por sexo, o IMVE foi de 159,9 &#177; 57,0 g/m<sup>2</sup> nos homens e de 148,0 &#177; 57,6 g/m<sup>2</sup> nas mulheres (p = 0,306). A <xref ref-type="table" rid="t4">tabela 4</xref> mostra os valores das vari&#225;veis ecocardiogr&#225;ficas estudadas.</p>
    <table-wrap id="t4">
      <graphic xlink:href="1678-4170-abc-93-04-0380-00011-gt04.jpg"/></table-wrap>
    <p>Fez-se o estudo da sensibilidade, especificidade e acur&#225;cia dos seis crit&#233;rios eletrocardiogr&#225;ficos avaliados na popula&#231;&#227;o geral, conforme mostra a <xref ref-type="table" rid="t05">tabela 5</xref>. As sensibilidades, especificidades e valores de p, de acordo com os padr&#245;es geom&#233;tricos de HVE na popula&#231;&#227;o geral (HVE conc&#234;ntrica: IMVE = 178,2 &#177; 54,8 g/m<sup>2</sup> e HVE exc&#234;ntrica: IMVE = 152,0 &#177; 38,2 g/m<sup>2</sup> - p = 0,028), s&#227;o mostradas na <xref ref-type="table" rid="t06">tabela 6</xref>. Entre os 17 (17%) pacientes que n&#227;o apresentavam HVE, o IMVE foi de 82,9 &#177; 13,6 g/m<sup>2</sup>.</p>
    <p content-type="asset">
      <table-wrap id="t05">
        <graphic xlink:href="1678-4170-abc-93-04-0380-00011-gt05.jpg"/></table-wrap>
    </p>
    <p content-type="asset">
      <table-wrap id="t06">
        <graphic xlink:href="1678-4170-abc-93-04-0380-00011-gt06.jpg"/></table-wrap>
    </p>
    <p>Para as vari&#225;veis cont&#237;nuas Sokolow-Lyon voltagem, Sokolow-Lyon produto, Cornell voltagem, Cornell produto e Romhilt-Estes, foram as seguintes as &#225;reas sob as curvas ROC: 0,85; 0,85; 0,85; 0,83 e 0,80, respectivamente.</p>
    <p>Procedendo-se &#224; correla&#231;&#227;o de Pearson para vari&#225;veis cont&#237;nuas, observou-se um coeficiente <underline>&gt;</underline> 0,50 entre o IMVE e as seguintes vari&#225;veis na popula&#231;&#227;o geral: Sokolow-Lyon produto, Cornell voltagem, Cornell produto e Romhilt-Estes. Quando se divide por sexo, a correla&#231;&#227;o de Pearson foi <underline>&gt;</underline>/ 0,50 entre o IMVE e todos os crit&#233;rios eletrocardiogr&#225;ficos avaliados, inclusive o QTc na popula&#231;&#227;o masculina. Entre as mulheres, a correla&#231;&#227;o foi <underline>&gt;</underline> 0,50 apenas entre o IMVE e os crit&#233;rios de Cornell voltagem e Cornell produto. Por ser o escore de Per&#250;gia uma vari&#225;vel categ&#243;rica, n&#227;o se pode efetuar a correla&#231;&#227;o de Pearson com o IMVE. Ver <xref ref-type="table" rid="t07">tabela 7</xref>.</p>
    <p content-type="asset">
      <table-wrap id="t07">
        <graphic xlink:href="1678-4170-abc-93-04-0380-00011-gt07.jpg"/></table-wrap>
    </p>
    <p>Conforme se v&#234; na <xref ref-type="table" rid="t8">tabela 8</xref>, o c&#225;lculo da raz&#227;o de verossimilhan&#231;a demonstra que todos os m&#233;todos eletrocardiogr&#225;ficos avaliados apresentam o poder discriminat&#243;rio do ECG no diagn&#243;stico de HVE na popula&#231;&#227;o estudada, com destaque para os crit&#233;rios de Cornell produto e Romhilt-Estes.</p>
    <table-wrap id="t8">
      <graphic xlink:href="1678-4170-abc-93-04-0380-00011-gt08.jpg"/></table-wrap>
    <p>Em rela&#231;&#227;o ao estudo da reprodutibilidade, o n&#237;vel de concord&#226;ncia intraobservador para as vari&#225;veis eletrocardiogr&#225;ficas Sokolow-Lyon voltagem, Romhilt-Estes e intervalo QT foi de 0,99; 0,97 e 0,96, respectivamente. A concord&#226;ncia interobservador para as mesmas vari&#225;veis foi de 0,99; 0,79 e 0,94, respectivamente. Para a vari&#225;vel massa do VE, obtida pelo ecocardiograma, o n&#237;vel de concord&#226;ncia intra e interobservador foi de 0,97 e 0,98, respectivamente.</p>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>A HVE geralmente leva a um aumento da amplitude do complexo QRS, com consequente desvio de orienta&#231;&#227;o para a esquerda e posterior das for&#231;as el&#233;tricas, disso originando ondas S profundas nas deriva&#231;&#245;es precordiais direitas. Por outro lado, a maior ativa&#231;&#227;o ventricular transversa, resultado da HVE, acarreta aumento na dura&#231;&#227;o do QRS e da deflex&#227;o intrinsec&#243;ide (intervalo entre o in&#237;cio da inscri&#231;&#227;o e o ponto m&#225;ximo do complexo QRS nas deriva&#231;&#245;es precordiais esquerdas)<sup>3,17</sup>.</p>
    <p>Indiscutivelmente, o ECG &#233; um exame complementar menos sens&#237;vel do que o ecocardiograma transtor&#225;cico na detec&#231;&#227;o da HVE. Por&#233;m, quando o processo &#233; diagnosticado por aquele m&#233;todo proped&#234;utico, encerra grave progn&#243;stico, com comprovado aumento da morbimortalidade cardiovascular. Conforme antes descrito, s&#227;o maiores os riscos de angina do peito, infarto do mioc&#225;rdio, acidente vascular cerebral, insufici&#234;ncia card&#237;aca e morte s&#250;bita<sup>17</sup>.</p>
    <p>O estudo de <italic>Framingham</italic>, em <italic>follow-up</italic> de 30 anos, demonstrou de maneira clara que o ECG com padr&#227;o de HVE aumentava a raz&#227;o de risco de eventos coronarianos de 3,0 a 5,8 vezes; os de acidente vascular cerebral de 3,2 a 7,0 vezes e os de insufici&#234;ncia card&#237;aca em at&#233; 17,5 vezes. Particularmente em rela&#231;&#227;o &#224; insufici&#234;ncia card&#237;aca, a possibilidade de desenvolv&#234;-la foi maior na presen&#231;a de um ECG compat&#237;vel com HVE do que mesmo de uma cardiomegalia observada &#224; radiografia de t&#243;rax<sup>18</sup>.</p>
    <p>As manifesta&#231;&#245;es de HVE ao ECG relacionadas a altera&#231;&#245;es da repolariza&#231;&#227;o ventricular do tipo <italic>strain</italic> (infradesn&#237;vel do segmento ST com convexidade para cima, associado a uma invers&#227;o assim&#233;trica da onda T nas deriva&#231;&#245;es precordiais e perif&#233;ricas esquerdas) parecem sinalizar tanto para a presen&#231;a de HVE, como de isquemia mioc&#225;rdica. Esse padr&#227;o, segundo o estudo de <italic>Framingham</italic>, aumentava o risco de complica&#231;&#245;es cardiovasculares em 5,8 vezes em homens e em 2,4 vezes em mulheres<sup>17</sup>. No estudo LIFE, o padr&#227;o <italic>strain</italic> ao ECG, observado em 971 pacientes, entre 8.854 avaliados em cinco anos, aumentou a mortalidade cardiovascular em 2,2 vezes, o risco de infarto do mioc&#225;rdio em 2,1 vezes e o de acidente vascular cerebral em 1,7 vez<sup>19</sup>.</p>
    <p>Sendo o ECG um exame de baixo custo e de excelente reprodutibilidade, apesar de suas conhecidas limita&#231;&#245;es no que diz respeito &#224; sensibilidade diagn&#243;stica, tem sido amplamente utilizado em estudos populacionais que avaliaram a preval&#234;ncia de HVE, sua regress&#227;o ou manuten&#231;&#227;o com interven&#231;&#227;o farmacol&#243;gica, sobretudo em pacientes hipertensos<sup>20-22</sup>.</p>
    <p>Por outro lado, n&#227;o se pode deixar de considerar que a maioria dos crit&#233;rios eletrocardiogr&#225;ficos para detec&#231;&#227;o de HVE foi validada em popula&#231;&#245;es com alta preval&#234;ncia de doen&#231;as cardiovasculares. A consequ&#234;ncia &#243;bvia &#233; a baixa <italic>performance</italic> desses crit&#233;rios quando aplicados em amostras com baixa preval&#234;ncia de tais doen&#231;as.</p>
    <p>Cabe salientar que n&#227;o havia o predom&#237;nio maci&#231;o de um sexo em rela&#231;&#227;o ao outro na amostra estudada, cujos indiv&#237;duos eram, na m&#233;dia, jovens (idade de 46,2 &#177; 14,0 anos), com IMC normal (m&#233;dia de 22,7 &#177; 3,7 kg/m<sup>2</sup>) e havia apenas quatro tabagistas (4%). Essa ressalva &#233; importante para contextualizar a popula&#231;&#227;o do estudo, de acordo com os quatro fatores que mais interferem com o diagn&#243;stico eletrocardiogr&#225;fico da HVE: sexo (sensibilidade maior nos homens); idade (a sensibilidade aumenta entre os mais idosos); peso (sensibilidade menor nos obesos) e tabagismo (sensibilidade menor nos fumantes)<sup>23</sup>.</p>
    <p>Alfakih e cols.<sup>24</sup>, em um estudo que envolveu 288 pacientes hipertensos, avaliaram quatro dos m&#233;todos eletrocardiogr&#225;ficos aqui pesquisados, encontrando cifras de sensibilidade e especificidade para os crit&#233;rios de Sokolow-Lyon voltagem, Sokolow-Lyon produto, Cornell voltagem e Cornell produto de 28,7% e 92,1%; 36,8% e 91,4%; 21,3% e 94,8%; 31,1% e 91,4%, respectivamente. O melhor desempenho verificado pelos seis crit&#233;rios eletrocardiogr&#225;ficos aqui avaliados pode ser atribu&#237;do ao perfil cl&#237;nico da amostra estudada, composta de pacientes graves, cujo IMVE foi muito elevado.</p>
    <p>Verdecchia e cols.<sup>22</sup>, estudando um novo m&#233;todo eletrocardiogr&#225;fico para diagn&#243;stico de HVE, o escore de Per&#250;gia, do estudo de PIUMA, encontraram uma preval&#234;ncia de 17,8% de HVE. No mesmo estudo, a preval&#234;ncia de HVE pelos crit&#233;rios de Cornell voltagem, Romhilt-Estes e Sokolow-Lyon voltagem foi de 9,1%, 5,2% e 13%, respectivamente.</p>
    <p>J&#225; no presente estudo, a <italic>performance</italic> do escore de Per&#250;gia, pela primeira vez testado em pacientes com DRC, foi excelente, com sensibilidade de 72,3%, especificidade de 82,4% e acur&#225;cia de 74%, o que tamb&#233;m pode ser explicado pela alta preval&#234;ncia de HVE.</p>
    <p>O c&#225;lculo da raz&#227;o de verossimilhan&#231;a demonstra que todos os crit&#233;rios eletrocardiogr&#225;ficos avaliados apresentam graus variados e expressivos de for&#231;a na detec&#231;&#227;o da HVE, talvez tamb&#233;m um reflexo da gravidade do grupo estudado. Entretanto, a combina&#231;&#227;o dos resultados da correla&#231;&#227;o de Pearson e da raz&#227;o de verossimilhan&#231;a mostra que o crit&#233;rio de Cornell produto foi o mais fidedigno na detec&#231;&#227;o de HVE na amostra avaliada.</p>
    <p>Stewart e cols.<sup>25</sup> encontraram correla&#231;&#227;o positiva entre intervalo QTc, dispers&#227;o do QTc e HVE com o grau de deteriora&#231;&#227;o da fun&#231;&#227;o renal. Por outro lado, Covic e cols.<sup>26</sup>, em estudo que incluiu 68 pacientes com DRC em est&#225;gio 5, n&#227;o-diab&#233;ticos, demonstraram que o processo de HD prolonga o intervalo QTc, mas n&#227;o a sua dispers&#227;o, em pacientes sem doen&#231;a card&#237;aca manifesta. Na amostra aqui estudada, de pacientes em di&#225;lise, o intervalo QTc manteve-se acima do limite superior da normalidade ( &gt; 440 ms) e a dispers&#227;o do QTc foi elevada (normal entre 50-60 ms<sup>27</sup>). Essa observa&#231;&#227;o pode ter relev&#226;ncia cl&#237;nica em vista da alta taxa de morte s&#250;bita nessa popula&#231;&#227;o. &#201; importante notar que n&#227;o houve correla&#231;&#227;o do QTc e dispers&#227;o do QTc com o IMVE. Essa falta de correla&#231;&#227;o sugere que as altera&#231;&#245;es do QTc e da sua dispers&#227;o estejam relacionadas mais a fatores metab&#243;licos do que propriamente &#224; HVE.</p>
    <p>Finalmente, fica o registro de que o ponto de corte para se estabelecer HVE em homens e mulheres, neste estudo, teve como base trabalhos ecocardiogr&#225;ficos. Frise-se que h&#225;, na literatura, estudos que utilizaram a pe&#231;a obtida em necropsia como padr&#227;o-ouro de correla&#231;&#227;o<sup>10,28</sup>. Por&#233;m, nessas condi&#231;&#245;es, s&#227;o maiores as possibilidades de distor&#231;&#245;es, uma vez que, dependendo do tempo e do estado cl&#237;nico do paciente antes da ocorr&#234;ncia do &#243;bito, o vi&#233;s pode ser relevante. Em nosso meio, Rodrigues e cols.<sup>29</sup>, estudando cora&#231;&#245;es necropsiados de indiv&#237;duos sadios, v&#237;timas de morte acidental, sugerem presen&#231;a de HVE quando a massa ventricular esquerda &#233; superior a 218 ou 128 g/m em homens e 148 ou 88 g/m em mulheres.</p>
    <p>
      <bold>Limita&#231;&#245;es do estudo</bold>
    </p>
    <p>Por tratar-se de uma amostra composta de pacientes graves, cujo perfil cl&#237;nico e elevado tempo em di&#225;lise j&#225; apontam para uma alta preval&#234;ncia de HVE, os resultados aqui apresentados talvez n&#227;o possam ser extrapolados para a popula&#231;&#227;o geral.</p>
    <p>
      <bold>Conclus&#227;o</bold>
    </p>
    <p>O ECG &#233; um m&#233;todo &#250;til, eficaz e de alta reprodutibilidade no diagn&#243;stico de HVE dos pacientes com DRC em est&#225;gio 5, em HD. Nessa popula&#231;&#227;o, o crit&#233;rio de Cornell produto mostrou-se o mais fidedigno na detec&#231;&#227;o de HVE. A despeito de apresentar menor sensibilidade do que o ecocardiograma, a utilidade do ECG &#233; real&#231;ada pela capacidade de detectar altera&#231;&#245;es eletrofisiol&#243;gicas, como o QTc e sua dispers&#227;o, que podem se correlacionar com a elevada ocorr&#234;ncia de morte s&#250;bita nessa popula&#231;&#227;o.</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>Este artigo &#233; parte de tese de Mestrado de Francisco de Assis Costa pela Universidade Federal de S&#227;o Paulo - Escola Paulista de Medicina.</p>
    <p>
      <fn id="back" fn-type="corresp">
        <label>
          <bold> Correspond&#234;ncia:</bold>
        </label>
        <p>Francisco de Assis Costa </p>
        <p> Av. Fernandes Lima Km. 05 </p>
        <p> Farol Hospital A&#231;&#250;car - Farol </p>
        <p> 57055-000 - Macei&#243;, AL, Brasil </p>
        <p> E-mail: </p>
        <p>
          <email xlink:href="facosta@cardiol.br">facosta@cardiol.br</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 25/08/08; revisado recebido em 31/10/08; aceito em 31/10/08</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Kannel WB, Gordon    T, Offutt D. Left ventricular hypertrophy by electrocardiogram: prevalence,    incidence, and mortality in the Framingham Study. Ann Intern Med. 1969; 71:    89-105.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Left ventricular hypertrophy by electrocardiogram: prevalence, incidence, and mortality in the Framingham Study</article-title>
          <source>Ann Intern Med</source>
          <date>
            <year>1969</year>
          </date>
          <fpage>89</fpage>
          <lpage>105</lpage>
          <volume>71</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kannel</surname>
              <given-names>WB</given-names>
            </name>
            <name>
              <surname>Gordon</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Offutt</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Levy D, Anderson    KM, Savage DD, Kannel WB, Christiansen JC, Castelli WP. Echocardiographically    detected left ventricular hypertrophy: prevalence and risk factors: the Framingham    Heart Study. Ann Intern Med. 1988; 108: 7-13.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors</article-title>
          <source>Ann Intern Med</source>
          <date>
            <year>1988</year>
          </date>
          <fpage>7</fpage>
          <lpage>13</lpage>
          <volume>108</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Levy</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Savage</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Kannel</surname>
              <given-names>WB</given-names>
            </name>
            <name>
              <surname>Christiansen</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Castelli</surname>
              <given-names>WP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Kannel WB. Prevalence    and natural history of electrocardiographic left ventricular hypertrophy. Am    J Med. 1983; Suppl 3A: 4-11.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prevalence and natural history of electrocardiographic left ventricular hypertrophy</article-title>
          <source>Am J Med</source>
          <date>
            <year>1983</year>
          </date>
          <fpage>4</fpage>
          <lpage>11</lpage>
          <person-group person-group-type="author">
            <name>
              <surname>Kannel</surname>
              <given-names>WB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Smilde TDJ,    Asselbegs FW, Hillege HL, Voors AA, Kors JA, Gansevoort RT, et al. Mild renal    dysfunction is associated with electrocardiographic left ventricular hypertrophy.    Am J Hypertens. 2005; 18: 342-47.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Mild renal dysfunction is associated with electrocardiographic left ventricular hypertrophy</article-title>
          <source>Am J Hypertens</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>342</fpage>
          <lpage>47</lpage>
          <volume>18</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Smilde</surname>
              <given-names>TDJ</given-names>
            </name>
            <name>
              <surname>Asselbegs</surname>
              <given-names>FW</given-names>
            </name>
            <name>
              <surname>Hillege</surname>
              <given-names>HL</given-names>
            </name>
            <name>
              <surname>Voors</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Kors</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Gansevoort</surname>
              <given-names>RT</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Foley RN, Parfrey    PS, Harnett JD, Kent GM, Martin CJ, Murray DC, et al. Clinical and echocardiographic    disease in patients starting end-stage renal disease therapy. Kidney Int. 1995;    47: 186-92.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Clinical and echocardiographic disease in patients starting end-stage renal disease therapy</article-title>
          <source>Kidney Int</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>186</fpage>
          <lpage>92</lpage>
          <volume>47</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Foley</surname>
              <given-names>RN</given-names>
            </name>
            <name>
              <surname>Parfrey</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Harnett</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Kent</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>DC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Sokolow M, Lyon    TP. The ventricular complex in left ventricular hypertrophy as obtained by unipolar    precordial and limb leads. Am Heart J. 1949; 37: 161-86.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads</article-title>
          <source>Am Heart J</source>
          <date>
            <year>1949</year>
          </date>
          <fpage>161</fpage>
          <lpage>86</lpage>
          <volume>37</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sokolow</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lyon</surname>
              <given-names>TP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Molloy TJ, Okin    PM, Devereux RB, Kligfield P. Electrocardiographic detection of left ventricular    hypertrophy by the simple QRS voltage-duration product. J Am Coll Cardiol. 1992;    20: 1180-86.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Electrocardiographic detection of left ventricular hypertrophy by the simple QRS voltage-duration product</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>1992</year>
          </date>
          <fpage>1180</fpage>
          <lpage>86</lpage>
          <volume>20</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Molloy</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Okin</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Devereux</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Kligfield</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Casalle PN,    Devereux RB, Alonso DR, Campo E, Kligfield P. Improved sex-specific criteria    of left ventricular hypertrophy for clinical and computer interpretation of    electrocadiograms: validation with autopsy findings. Circulation. 1987; 75 (3):    565-72.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocadiograms: validation with autopsy findings</article-title>
          <source>Circulation</source>
          <date>
            <year>1987</year>
          </date>
          <fpage>565</fpage>
          <lpage>72</lpage>
          <issue>3</issue>
          <volume>75</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Casalle</surname>
              <given-names>PN</given-names>
            </name>
            <name>
              <surname>Devereux</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Alonso</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Campo</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kligfield</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Okin PM, Roman    MJ, Devereux RB, Kligfield P. Electrocardiographic identification of increased    left ventricular mass by simple voltage-duration products. J Am Coll Cardiol.    1995; 25 (2): 417-23.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>417</fpage>
          <lpage>23</lpage>
          <issue>2</issue>
          <volume>25</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Okin</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Roman</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Devereux</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Kligfield</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Romhilt DW,    Estes EH. A point-score system for the ECG diagnosis of left ventricular hypertrophy.    Am Heart J. 1968; 75: 752-58.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>A point-score system for the ECG diagnosis of left ventricular hypertrophy</article-title>
          <source>Am Heart J</source>
          <date>
            <year>1968</year>
          </date>
          <fpage>752</fpage>
          <lpage>58</lpage>
          <volume>75</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Romhilt</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Estes</surname>
              <given-names>EH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Schillaci G,    Verdecchia P, Borgioni C, Ciucci A, Guerrieri M, Zampi I, et al. Improved electrocardiographic    diagnosis of left ventricular hypertrophy. Am J Cardiol. 1994; 74: 714-19</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Improved electrocardiographic diagnosis of left ventricular hypertrophy</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>1994</year>
          </date>
          <fpage>714</fpage>
          <lpage>19</lpage>
          <volume>74</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Schillaci</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Verdecchia</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Borgioni</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ciucci</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Guerrieri</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zampi</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Sociedade Brasileira    de Cardiologia. Diretriz para indica&#231;&#245;es e utiliza&#231;&#227;o    da ecocardiografia na pr&#225;tica cl&#237;nica. Arq Bras Cardiol. 2004;    82 (Supl II): 1-34.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Diretriz para indica&#231;&#245;es e utiliza&#231;&#227;o da ecocardiografia na pr&#225;tica cl&#237;nica</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>1</fpage>
          <lpage>34</lpage>
          <volume>82</volume>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Lang RM, Bierig    M, Devereux RB, Flachskampf FA; Foster E, Pellikka PA, et al. Recommendations    for chamber quantification: a report from the American of Echocardiography's    guidelines and standards committee and the chamber quantification writing group,    developed in conjunction with the European Association of Echocardiography,    a branch of the European Society of Cardiology. J Am Echocardiogr. 2005; 18:    1440-63.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Recommendations for chamber quantification: a report from the American of Echocardiography's guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology</article-title>
          <source>J Am Echocardiogr</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>1440</fpage>
          <lpage>63</lpage>
          <volume>18</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lang</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Bierig</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Devereux</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Flachskampf</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Foster</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Pellikka</surname>
              <given-names>PA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Devereux RB,    Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I. Echocardiographic assessment    of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol.1986;    57: 450-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>1986</year>
          </date>
          <fpage>450</fpage>
          <lpage>8</lpage>
          <volume>57</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Devereux</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Alonso</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Lutas</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Gottlieb</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Campo</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Sachs</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Mosteller RD.    Simplified calculation of body-surface area. N Engl J Med. 1987; 317: 1098.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Simplified calculation of body-surface area</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>1987</year>
          </date>
          <fpage>1098</fpage>
          <volume>317</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mosteller</surname>
              <given-names>RD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Roman MJ, Klingfield    R, Devereux RB. Geometric and functional correlates of electrocardiographic    repolarization and voltage abnormalities in aortic regurgitacion and limb leads.    Am Heart J. 1987; 37: 161-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Geometric and functional correlates of electrocardiographic repolarization and voltage abnormalities in aortic regurgitacion and limb leads</article-title>
          <source>Am Heart J</source>
          <date>
            <year>1987</year>
          </date>
          <fpage>161</fpage>
          <lpage>8</lpage>
          <volume>37</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Roman</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Klingfield</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Devereux</surname>
              <given-names>RB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Levy D, Salomon    M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline    electrocardiographic features and their serial changes in subjects with left    ventricular hypertrophy. Circulation. 1994; 90: 1786-93.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy</article-title>
          <source>Circulation</source>
          <date>
            <year>1994</year>
          </date>
          <fpage>1786</fpage>
          <lpage>93</lpage>
          <volume>90</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Levy</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Salomon</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>D'Agostino</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Belanger</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Kannel</surname>
              <given-names>WB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Kannel WB,    Levy D, Cupples LA. Left ventricular hypertrophy and risk of cardiac failure:    insights from the Framingham Study. J Cardiovasc Pharmacol. 1987;10 (Suppl 6):    S135-40.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Left ventricular hypertrophy and risk of cardiac failure: insights from the Framingham Study</article-title>
          <source>J Cardiovasc Pharmacol</source>
          <date>
            <year>1987</year>
          </date>
          <fpage>S135</fpage>
          <lpage>40</lpage>
          <volume>10</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kannel</surname>
              <given-names>WB</given-names>
            </name>
            <name>
              <surname>Levy</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Cupples</surname>
              <given-names>LA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. Okin PM, Devereux    RB, Jern Sverker, Julius S, Kjeldsen SE, Dahl&#246;f B. Relation of echocardiographic    left ventricular mass and hypertrophy to persistent electrocardiographic left    ventricular hypertrophy in hypertensive patients: The LIFE Study. Am J Hypertens.    2001; 14: 775-82.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Relation of echocardiographic left ventricular mass and hypertrophy to persistent electrocardiographic left ventricular hypertrophy in hypertensive patients: The LIFE Study</article-title>
          <source>Am J Hypertens</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>775</fpage>
          <lpage>82</lpage>
          <volume>14</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Okin</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Devereux</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Jern Sverker</surname>
            </name>
            <name>
              <surname>Julius</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kjeldsen</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Dahl&#246;f</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. Julius S, Kjeldsen    SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive    patients in high cardiovascular risk treated with regimens based on valsartan    and amlodipine: the VALUE randomised trial. Lancet. 2004; 363: 2022-31.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Outcomes in hypertensive patients in high cardiovascular risk treated with regimens based on valsartan and amlodipine: the VALUE randomised trial</article-title>
          <source>Lancet</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>2022</fpage>
          <lpage>31</lpage>
          <volume>363</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Julius</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kjeldsen</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Weber</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Brunner</surname>
              <given-names>HR</given-names>
            </name>
            <name>
              <surname>Ekman</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hansson</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21. Dahl&#246;f    B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, De Faire U, et al. Cardiovascular    morbidity and mortality in the Losartan Intervention For Endpoint reduction    in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;    359: 995-1003.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol</article-title>
          <source>Lancet</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>995</fpage>
          <lpage>1003</lpage>
          <volume>359</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Dahl&#246;f</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Devereux</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Kjeldsen</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Julius</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Beevers</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>De Faire</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>22. Verdecchia    P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, et al. Prognostic    value of a new electrocardiographic method for diagnosis of left ventricular    hypertrophy. J Am Coll Cardiol. 1998; 31: 383-90.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prognostic value of a new electrocardiographic method for diagnosis of left ventricular hypertrophy</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>383</fpage>
          <lpage>90</lpage>
          <volume>31</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Verdecchia</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Schillaci</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Borgioni</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ciucci</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gattobigio</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Zampi</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B23">
        <mixed-citation>23. Levy D, Labib    SB, Anderson KM, Christiansen JC, Kannel WB, Castelli WP. Determinants of sensitivity    and specificity of electrocardiographic criteria for left ventricular hypertrophy.    Circulation. 1994; 81: 815-20.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Determinants of sensitivity and specificity of electrocardiographic criteria for left ventricular hypertrophy</article-title>
          <source>Circulation</source>
          <date>
            <year>1994</year>
          </date>
          <fpage>815</fpage>
          <lpage>20</lpage>
          <volume>81</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Levy</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Labib</surname>
              <given-names>SB</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Christiansen</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Kannel</surname>
              <given-names>WB</given-names>
            </name>
            <name>
              <surname>Castelli</surname>
              <given-names>WP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B24">
        <mixed-citation>24. Alfakih K,    Walters K, Jones T, Ridgway J, Hall AS, Sivannanthan M. New gender-specific    partition values for ECG criteria of left ventricular hypertrophy: recalibration    against cardiac MRI. Hypertension. 2004; 44: 175-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>New gender-specific partition values for ECG criteria of left ventricular hypertrophy: recalibration against cardiac MRI</article-title>
          <source>Hypertension</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>175</fpage>
          <lpage>9</lpage>
          <volume>44</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Alfakih</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Walters</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ridgway</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hall</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Sivannanthan</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B25">
        <mixed-citation>25. Stewart GA,    Gansevoort RT, Mark PB, Rooney E, McDonagh TA, Dargie HJ, et al. Electrocardiographic    abnormalities and uremic cardiomyopathy. Kidney Int. 2005; 67: 217-26.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Electrocardiographic abnormalities and uremic cardiomyopathy</article-title>
          <source>Kidney Int</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>217</fpage>
          <lpage>26</lpage>
          <volume>67</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Stewart</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Gansevoort</surname>
              <given-names>RT</given-names>
            </name>
            <name>
              <surname>Mark</surname>
              <given-names>PB</given-names>
            </name>
            <name>
              <surname>Rooney</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>McDonagh</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Dargie</surname>
              <given-names>HJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B26">
        <mixed-citation>26. Covic A, Diaconita    M, Gusbeth-Tatomir P, Covic M, Botezan A, Ungureanu G, et al. Haemodialysis    increases QTc interval but not QTc dispersion in ESRD patients without manifest    cardiac disease. Nephrol Dial Transplant. 2002; 17: 2170-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Haemodialysis increases QTc interval but not QTc dispersion in ESRD patients without manifest cardiac disease</article-title>
          <source>Nephrol Dial Transplant</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>2170</fpage>
          <lpage>7</lpage>
          <volume>17</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Covic</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Diaconita</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gusbeth-Tatomir</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Covic</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Botezan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ungureanu</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B27">
        <mixed-citation>27. Van de Loo    A, Arendts W, Hohnloser SH. Variability of QT dispersion measurements in the    surface electrocardiogram in patients with acute myocardial infarction and in    normal subjects. Am J Cardiol. 1994; 74: 1113-18.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Variability of QT dispersion measurements in the surface electrocardiogram in patients with acute myocardial infarction and in normal subjects</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>1994</year>
          </date>
          <fpage>1113</fpage>
          <lpage>18</lpage>
          <volume>74</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Van de Loo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Arendts</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Hohnloser</surname>
              <given-names>SH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B28">
        <mixed-citation>28. Mazzoleni A,    Wolff R, Wolff L, Reiner L. Correlation between component cardiac weights and    electrocardiographic patterns in 185 cases. Circulation. 1964; 30: 808-29.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Correlation between component cardiac weights and electrocardiographic patterns in 185 cases</article-title>
          <source>Circulation</source>
          <date>
            <year>1964</year>
          </date>
          <fpage>808</fpage>
          <lpage>29</lpage>
          <volume>30</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mazzoleni</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Wolff</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Wolff</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Reiner</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B29">
        <mixed-citation>29. Rodrigues SL,    Pimentel EB, Mill JG. Peso dos ventr&#237;culos card&#237;acos determinado    em necropsia de indiv&#237;duos saud&#225;veis mortos por causas externas.    Arq Bras Cardiol. 2007; 89 (5): 279-84.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Peso dos ventr&#237;culos card&#237;acos determinado em necropsia de indiv&#237;duos saud&#225;veis mortos por causas externas</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>279</fpage>
          <lpage>84</lpage>
          <issue>5</issue>
          <volume>89</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rodrigues</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Pimentel</surname>
              <given-names>EB</given-names>
            </name>
            <name>
              <surname>Mill</surname>
              <given-names>JG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Electrocardiography in the diagnosis of ventricular hypertrophy in patients with chronic renal disease</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>BACKGROUND: Left ventricular hypertrophy (LVH) is an independent predictor of cardiovascular risk, and its characterization and prevalence in chronic renal disease (CRD) should be further studied. OBJECTIVE: To establish the diagnosis of LVH in patients with stage-5 CRD using six different electrocardiographic criteria, and to correlate them with left ventricular mass index (LVMI) as obtained by echocardiography. METHODS: Cross-sectional study including 100 patients (58 men and 42 women, mean age 46.2 &#177; 14.0 years) with CRD of all causes undergoing hemodialysis (HD) for at least six months. Electrocardiography (ECG) and echocardiography were performed in all patients, always up to one hour after the end of the HD sessions. RESULTS: LVH was detected in 83 patients (83%), of whom 56 (67.4%) had the concentric pattern and 27 (32.6%) the eccentric pattern of LVH. Diagnostic sensitivity, specificity and accuracy of all the electrocardiographic methods studied were higher than 50%. Using Pearson's linear correlation for LVMI, only the Sokolow-Lyon voltage criterion did not show a &gt; 0.50 coefficient. Calculation of the likelihood ratio, in turn, showed that ECG has a discriminatory power for the diagnosis of LVH in the population studied, with emphasis on the Cornell-product and Romhilt-Estes criteria. No correlation was observed between LVMI and QTc and QTc dispersion. CONCLUSION: ECG is a useful, efficient, and highly reproducible method for the diagnosis of LVH in HD patients. In this population, the Cornell-product proved to be the most reliable criterion for the detection of LVH.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Kidney diseases</kwd>
        <kwd>echocardiography</kwd>
        <kwd>electrocardiography</kwd>
        <kwd>renal dialysis</kwd>
        <kwd>hypertrophy, left ventricular</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ORIGINAL ARTICLE</bold>
      </p>
      <p>
        <fn id="top-body2">
          <label>
            <bold>Electrocardiography in the diagnosis of ventricular hypertrophy in patients with chronic renal disease </bold>
          </label>
          <p>
            <bold>Francisco de Assis Costa<sup>I</sup>; Ivan Romero Rivera<sup>I</sup>; Mirian Lira Castro de Vasconcelos<sup>I</sup>; Andr&#233; Falc&#227;o Pedrosa Costa<sup>I</sup>; Rui Manoel dos Santos P&#243;voa<sup>II</sup>; Maria Tereza Nogueira Bombig<sup>II</sup>; Br&#225;ulio Luna Filho<sup>II</sup>; Valter Correia de Lima<sup>II</sup></bold>
          </p>
        </fn>
      </p>
      <p><sup>I</sup>Universidade Estadual de Ci&#234;ncias da Sa&#250;de de Alagoas-UNCISAL, Macei&#243;, AL</p>
      <p><sup>II</sup>Universidade Federal de S&#227;o Paulo-Escola Paulista de Medicina-UNIFESP-EPM, S&#227;o Paulo, SP, Brasil</p>
      <p>Mailing Address</p>
      <p>
        <bold>SUMMARY</bold>
      </p>
      <p><bold>BACKGROUND:</bold> Left ventricular hypertrophy (LVH) is an independent predictor of cardiovascular risk, and its characterization and prevalence in chronic renal disease (CRD) should be further studied.</p>
      <p><bold>OBJECTIVE:</bold> To establish the diagnosis of LVH in patients with stage-5 CRD using six different electrocardiographic criteria, and to correlate them with left ventricular mass index (LVMI) as obtained by echocardiography.</p>
      <p><bold>METHODS:</bold> Cross-sectional study including 100 patients (58 men and 42 women, mean age 46.2 &#177; 14.0 years) with CRD of all causes undergoing hemodialysis (HD) for at least six months. Electrocardiography (ECG) and echocardiography were performed in all patients, always up to one hour after the end of the HD sessions.</p>
      <p><bold>RESULTS:</bold> LVH was detected in 83 patients (83%), of whom 56 (67.4%) had the concentric pattern and 27 (32.6%) the eccentric pattern of LVH. Diagnostic sensitivity, specificity and accuracy of all the electrocardiographic methods studied were higher than 50%. Using Pearson's linear correlation for LVMI, only the Sokolow-Lyon voltage criterion did not show a <underline>&gt;</underline> 0.50 coefficient. Calculation of the likelihood ratio, in turn, showed that ECG has a discriminatory power for the diagnosis of LVH in the population studied, with emphasis on the Cornell-product and Romhilt-Estes criteria. No correlation was observed between LVMI and QTc and QTc dispersion.</p>
      <p><bold>CONCLUSION:</bold> ECG is a useful, efficient, and highly reproducible method for the diagnosis of LVH in HD patients. In this population, the Cornell-product proved to be the most reliable criterion for the detection of LVH.</p>
      <p><bold>Key Words:</bold> Kidney Diseases; Echocardiography; Electrocardiography; Renal Dialysis; Hypertrophy, Left Ventricular.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>LVH is an independent predictor of morbidity and mortality in the general population when diagnosed by either ECG or echocardiography<sup>1,2</sup>.</p>
      <p>Since the pioneering observations of the Framingham Heart Study, several epidemiological studies pointed out LVH as one of the most important risk factors for angina pectoris, myocardial infarction, heart failure, stroke and sudden death<sup>3</sup>.</p>
      <p>Little information is available on the population of patients with different stages of CRD. The PREVEND study used the Cornell product electrocardiographic criterion to analyze the presence of LVH in individuals with renal dysfunction, defined as a glomerular filtration rate (GFR) &lt; 60mL/min/1.73 m<sup>2</sup> or microalbuminuria, and found a prevalence of 5.3%<sup>4</sup>. Studies using echocardiography, in turn, estimate the prevalence of LVH in patients with stage-5 CRD, that is, those with a GFR &lt; 15 mL/min/1.73m<sup>2</sup> or undergoing renal replacement therapy, at between 40% and 74%<sup>5</sup>.</p>
      <p>LVH can be detected by ECG, chest radiography, echocardiography and magnetic resonance imaging. However, in the clinical practice, ECG and echocardiography are the most frequently used methods, not only for being more readily available, but mainly for the prognostic relationship that clearly predicts an increased cardiovascular risk when LVH is observed<sup>3</sup>.</p>
      <p>The main objective of this study was to establish the diagnosis of LVH in stage-5 CRD patients using six different electrocardiographic criteria, and to correlate them with LVMI as diagnosed by echocardiography.</p>
      <p>
        <bold>Methods</bold>
      </p>
      <p>
        <bold>Patients</bold>
      </p>
      <p>From June 2006 to February 2007, 133 patients with stage-5 CRD of any cause, who were clinically stable and undergoing HD for at least six months were evaluated in <italic>Funda&#231;&#227;o Hospital da Agroind&#250;stria do A&#231;&#250;car e do &#193;lcool de Alagoas</italic> (<xref ref-type="table" rid="t1-body2">Table 1</xref>). The protocol was approved by the Human Research Ethics Committee of <italic>Universidade Estadual de Ci&#234;ncias da Sa&#250;de de Alagoas</italic> and a written informed consent was obtained from all patients, according to the principles of the Declaration of Helsinki. The exclusion criteria were: history of chronic or acute coronary syndrome (regardless of duration); heart valve disease; cardiomyopathy of any cause as diagnosed by transthoracic echocardiography; pericardial effusion; patients using pacemaker; right or left bundle branch block; ventricular pre-excitation syndromes; and any rhythm other than sinus rhythm, that is, any factor that could potentially interfere with the electrocardiographic analysis of LVH. Of the 133 patients screened, 33 were excluded. All the 100 patients selected were interviewed. On that occasion, casual blood pressure was taken, and ECG and transthoracic echocardiography were performed, always up to one hour after the end of the HD sessions.</p>
      <table-wrap id="t1-body2">
        <graphic xlink:href="1678-4170-abc-93-04-0380-00011-gt01-en.jpg"/></table-wrap>
      <p>
        <bold>Electrocardiography</bold>
      </p>
      <p>Twelve-lead resting ECG was performed with the patient in the supine position; the recording speed was 25 mm/s, and calibration was standardized at 1 mV/cm (Dixtal equipment, model EP3<sup>&#174;</sup>, Brazil). The electrocardiographic tracings were analyzed by one single observer, who was an experienced cardiologist with no connection with the performance of the echocardiograms. All measurements were taken manually, and noted down as follows: amplitude (mm) of P wave, R waves in aV<sub>L</sub>, S in V<sub>3</sub>, S in V<sub>1</sub>, R in V<sub>5</sub> or V<sub>6</sub>, and larger R and S waves in the horizontal plane; duration (ms) of P wave, of QRS complex, of ventricular activation, of QT interval corrected by Bazzet's formula (mean of the 12 leads); and of QT dispersion (QT maximum - QT minimum). Six electrocardiographic criteria for the diagnosis of LVH were also evaluated: 1) Sokolow-Lyon voltage (SV<sub>1</sub> + RV<sub>5</sub> or V<sub>6</sub><underline>&gt;</underline> 35 mm)<sup>6</sup>; 2) Sokolow-Lyon product (SV<sub>1</sub> + RV<sub>5</sub> or V<sub>6</sub> X QRS duration <underline>&gt;</underline> 3000 mm.ms for women and <underline>&gt;</underline> 4000 mm.ms for men)<sup>7</sup>; 3) Cornell voltage (RaV<sub>L</sub> + SV<sub>3</sub><underline>&gt;</underline> 20 mm for women and <underline>&gt;</underline> 28 mm for men)<sup>8</sup>; 4) Cornell product (RaV<sub>L</sub> + SV<sub>3</sub> X QRS duration <underline>&gt;</underline> 2440 mm.ms, add 6 mm for women)<sup>9</sup>; 5) Romhilt-Estes point score: larger R or S amplitude <underline>&gt;</underline> 30 mm in the horizontal plane or <underline>&gt;</underline> 20 mm in the frontal plane, or strain pattern in V<sub>5</sub> or V<sub>6</sub> (if on digitalis, it is worth only one point) or left atrial enlargement according to Morris index (three points); &#194;QRS electrical axis higher than minus 30 degrees (two points); QRS duration <underline>&gt;</underline> 90 ms in V<sub>5</sub> or V<sub>6</sub> or ventricular activation time <underline>&gt;</underline> 50 ms in V<sub>5</sub> or V<sub>6</sub> (one point). Using this score, LVH is diagnosed when the sum of points is <underline>&gt;</underline> 5<sup>10</sup>; 6) Perugia score: LVH is diagnosed by the presence of one or more of the following findings - Cornell criterion, considering the limit of <underline>&gt;</underline> 20 mm for women and <underline>&gt;</underline> 24 mm for men, Romhilt-Estes score and strain pattern<sup>11</sup>. The study of reproducibility of the method was carried out by the same observer at two different timepoints, so that the first reading could not be recalled and identified, and by an independent observer who was a PhD Cardiologist with a vast experience in electrocardiography; this study was based on the analysis of 30 randomly chosen tracings for the assessment of the Sokolow-Lyon voltage, Romhilt-Estes and QT interval variables.</p>
      <p>
        <bold>Echocardiography</bold>
      </p>
      <p>The studies were performed by two echocardiographers accredited by the Department of Echocardiography of the Brazilian Society of Cardiology strictly following the standards established by the Guideline for Indications and Use of Echocardiography in the Clinical Practice<sup>12</sup>. We should underscore that none of these two observers had any relation with the analysis of the ECG tracings. The patients were placed in the left lateral position and a Caris<sup>&#174;</sup> ultrasound scanner (Esaote-Biom&#233;dica, Italy) equipped with a 2.5 MHz transducer was used. The usual views were used to obtain a full study in the M, two-dimensional, and pulsed Doppler modes, with simultaneous continuous ECG recording. According to the recommendations of the American Society of Echocardiography / European Association of Echocardiography<sup>13</sup>, interventricular septal (IVSD) thickness and left ventricular posterior wall (LVPWD) thickness were obtained at diastole, and LV mass, in grams, was calculated using the formula: LV mass = 0.8 X {1.04 [(IVSD + EDLVD + LVPWD)<sup>3</sup> - (EDLVD)<sup>3</sup>]} + 0.6 g<sup>14</sup>, where IVSD is the diastolic interventricular septal thickness, EDLVD is the end-diastolic LV diameter, and LVPWD is the diastolic left ventricular posterior wall. LV mass was corrected for the body surface area. Echocardiographic diagnosis of LVH was made when LVMI was &gt; 88 g/m<sup>2</sup> for women and &gt; 102 g/m<sup>2</sup> for men<sup>13</sup>. The relative LV wall thickness (RWT) was also calculated using the formula RWT = 2 X LVPWD/EDLVD, where LVPWD is the diastolic LV posterior wall and EDLVD is the end-diastolic LV diameter.</p>
      <p>From the calculation of RWT, two geometric patterns of LVH could be established: a concentric pattern, when RWT was <underline>&gt;</underline> 0.42 and an eccentric pattern, when RWT <underline>&lt;</underline> 0.42<sup>13</sup>. The LV systolic function was evaluated by means of the LV fractional shortening and LV ejection fraction as obtained using the Teicholz method. The analysis of reproducibility of the method was carried out in 30 randomly chosen participants who had their LV mass calculated using Devereux's formula<sup>14</sup>. The same echocardiographic study was evaluated by one observer at two different timepoints, like in the electrocardiographic analysis. The study was then read by another observer who was blind to the readings of the first observer.</p>
      <p>
        <bold>Anthropometric measurements</bold>
      </p>
      <p>Weight and height were measured, always up to one hour after the end of the dialysis sessions. Body surface area, in m<sup>2</sup>, was calculated according to Mosteller's equation (0.20247 X weight<sup>0.425</sup> X height<sup>0.725</sup>)<sup>15</sup>. Body mass index was calculated by dividing weight (Kg) by the square height (m).</p>
      <p>
        <bold>Statistical analysis</bold>
      </p>
      <p>Continuous variables were expressed as means and standard deviation and categorical variables as percentages. Association between LVMI and the other variables of interest was made using the Pearson's correlation coefficient. For this study, only Pearson's coefficient <underline>&gt;</underline> 0.50 was considered significant. The ROC curve was used to analyze the sensitivity, specificity and accuracy of the six electrocardiographic criteria studied, except for Perugia score (categorical variable). Fisher's exact test was used for the comparison of sensitivities of the electrocardiographic methods studied, according to the geometric patterns of LVH. Student's t test was used to compare the LVMI between men and women. The likelihood ratio for the electrocardiographic criteria was also calculated. The assessment of reproducibility of the two methods used was made by three independent observers in different occasions, using Lin's concordance coefficient. In all comparisons, 95% confidence intervals and p &lt; 0.05 were considered statistically significant.</p>
      <p>
        <bold>Results</bold>
      </p>
      <p>Of the 100 patients who completed the study, 58 were males (58%) and 42 were females (42%), with mean age of 46.2 &#177; 14.0 years (ranging from 18 to 78 years) and mean HD time of 50.7 &#177; 46.5 months (ranging from 6 to 225 months, median of 33.5 months). Demographics and clinical characteristics of the patients are shown in <xref ref-type="table" rid="t2-body2">Table 2</xref>, and electrocardiographic findings in <xref ref-type="table" rid="t3-body2">Table 3</xref>.</p>
      <table-wrap id="t2-body2">
        <graphic xlink:href="1678-4170-abc-93-04-0380-00011-gt02-en.jpg"/></table-wrap>
      <table-wrap id="t3-body2">
        <graphic xlink:href="1678-4170-abc-93-04-0380-00011-gt03-en.jpg"/></table-wrap>
      <p>The prevalence of LVH on echocardiography was 83%; 56 (67.4%) and 27 (32.6%) of these patients had concentric and eccentric LVH, respectively. The mean LVMI in the population studied was 154.9 &#177; 57.3 g/m<sup>2</sup>. In relation to gender, the mean LVMI was 159.9 &#177; 57.0 g/m<sup>2</sup> in men and 148.0 &#177; 57.6 g/m<sup>2</sup> in women (p = 0.306). Values of the echocardiographic variables studied are shown in <xref ref-type="table" rid="t4-body2">Table 4</xref>.</p>
      <table-wrap id="t4-body2">
        <graphic xlink:href="1678-4170-abc-93-04-0380-00011-gt04-en.jpg"/></table-wrap>
      <p>Studies of sensitivity, specificity and accuracy of the six electrocardiographic criteria assessed in the general population are shown in <xref ref-type="table" rid="en_11t05-body2">Table 5</xref>. Sensitivities, specificities and p values, according to the geometric patterns of LVH in the general population (concentric LVH: LVMI = 178.2 &#177; 54.8 g/m<sup>2</sup> and eccentric LVH: LVMI = 152.0 &#177; 38.2 g/m<sup>2</sup> - p = 0.028) are shown in <xref ref-type="table" rid="en_11t06-body2">Table 6</xref>. Among the 17 (17%) patients who did not present LVH, the mean LVMI was 82.9 &#177; 13.6 g/m<sup>2</sup>.</p>
      <p content-type="asset">
        <table-wrap id="en_11t05-body2">
          <graphic xlink:href="1678-4170-abc-93-04-0380-00011-gt05-en.jpg"/></table-wrap>
      </p>
      <p content-type="asset">
        <table-wrap id="en_11t06-body2">
          <graphic xlink:href="1678-4170-abc-93-04-0380-00011-gt06-en.jpg"/></table-wrap>
      </p>
      <p>The areas under the ROC curves for the Sokolow-Lyon voltage, Sokolow-Lyon product, Cornell voltage, Cornell product and Romhilt-Estes continuous variables were 0.85, 0.85, 0.85, 0.83 and 0.80, respectively.</p>
      <p>Using Pearson's correlation for continuous variables, we observed a <underline>&gt;</underline> 0.50 coefficient between LVMI and the following variables in the general population: Sokolow-Lyon product, Cornell voltage, Cornell product, and Romhilt-Estes. When applied to gender, Pearson's correlation was <underline>&gt;</underline> 0.50 between LVMI and all the electrocardiographic criteria assessed and QTc in the male population. Among women, the correlation was <underline>&gt;</underline> 0.50 only between LVMI and the Cornell voltage and Cornell product criteria. Since Perugia score is a categorical variable, Pearson's correlation cannot be used with LVMI (<xref ref-type="table" rid="en_11t07-body2">Table 7</xref>).</p>
      <p content-type="asset">
        <table-wrap id="en_11t07-body2">
          <graphic xlink:href="1678-4170-abc-93-04-0380-00011-gt07-en.jpg"/></table-wrap>
      </p>
      <p>As can be observed in <xref ref-type="table" rid="en_11t08-body2">Table 8</xref>, calculation of the likelihood ratio demonstrates that all electrocardiographic methods assessed show the discriminatory power of ECG in the diagnosis of LVH in the population studied, with special emphasis to the Cornell product and Romhilt-Estes criteria.</p>
      <p content-type="asset">
        <table-wrap id="en_11t08-body2">
          <graphic xlink:href="1678-4170-abc-93-04-0380-00011-gt08-en.jpg"/></table-wrap>
      </p>
      <p>In relation to the analysis of reproducibility, the intraobserver concordance level for the Sokolow-Lyon voltage, Romhilt-Estes and QT interval electrocardiographic variables was 0.99, 0.97, and 0.96, respectively. The interobserver concordance for the same variables was 0.99, 0.79, and 0.94, respectively. For the LV mass variable, as obtained by echocardiography, the intra and interobserver concordance levels were 0.97 and 0.98, respectively.</p>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>LVH usually leads to increased amplitude of the QRS complex, with a subsequent leftward and posterior shift of the electrical forces, thus resulting in deep S waves in right precordial leads. On the other hand, the greater cross-sectional ventricular activation caused by LVH results in increased QRS duration and intrinsecoid deflection (interval between the beginning of the inscription and maximum point of the QRS complex in left precordial leads)<sup>3,17</sup>.</p>
      <p>ECG is undoubtedly a less sensitive test than transthoracic echocardiography for the diagnosis of LVH. However, when LVH is detected by ECG, the patient's prognosis is very poor, with proved increased cardiovascular morbidity and mortality. As previously described, there is a higher risk of angina pectoris, myocardial infarction, stroke, heart failure and sudden death<sup>17</sup>.</p>
      <p>The Framingham study, with a 30-year follow-up, clearly demonstrated that in the presence of electrocardiographic LVH, there was an increased risk for coronary events by 3.0 to 5.8 times; for stroke by 3.2 to 7.0 times; and for heart failure by up to 17.5 times. Particularly in relation to heart failure, the risk of developing this condition was higher in the presence of an ECG consistent with LVH than in the presence of enlarged heart as observed on chest radiography<sup>18</sup>.</p>
      <p>LVH manifestations on ECG related to strain-pattern ventricular repolarization changes (ST-segment depression with upward convexity associated with asymmetrical T-wave inversion in left limb and precordial leads) seem to indicate both the presence of LVH and myocardial ischemia. According to the Framingham study, this pattern increases the risk of cardiovascular complications by 5.8 times in men and 2.4 times in women<sup>17</sup>. In the LIFE study, the ECG strain pattern observed in 971 out of 8854 patients evaluated over a period of five years increased the cardiovascular mortality by 2.2 times, the risk of myocardial infarction by 2.1 times, and the risk of stroke by 1.7 times<sup>19</sup>.</p>
      <p>ECG is a low-cost, highly reproducible test, and despite the known limitations regarding its diagnostic sensitivity, it has been widely used in population-based studies assessing the prevalence of LVH, and its regression or persistence with pharmacological intervention, especially in hypertensive patients<sup>20-22</sup>.</p>
      <p>On the other hand, we cannot disregard that the majority of the electrocardiographic criteria used for the detection of LVH was validated in populations with a high prevalence of cardiovascular diseases. The obvious consequence is a poor performance of these criteria when applied to samples with a low prevalence of these diseases.</p>
      <p>We should point out that no overwhelming predominance of one gender over the other was observed in the study sample, which was comprised, on average, of young individuals (age from 46.2 &#177; 14.0 years) who had normal BMI (mean of 22.7 &#177; 3.7 Kg/m<sup>2</sup>), and only four were smokers (4%). This observation is important to contextualize the study population according to the four factors that most interfere with the electrocardiographic diagnosis of LVH: gender (higher sensitivity in men); age (sensitivity increases among the oldest); weight (lower sensitivity in obese individuals); and smoking (lower sensitivity in smokers)<sup>23</sup>.</p>
      <p>Alfakih et al<sup>24</sup> conducted a study in 288 hypertensive patients and assessed four of the electrocardiographic methods used in the present study. They found values of sensitivity and specificity for the Sokolow-Lyon voltage, Sokolow-Lyon product, Cornell voltage and Cornell product criteria of 28.7% and 92.1%; 36.8% and 91.4%; 21.3% and 94.8%; 31.1% and 91.4%, respectively. The better performance of the six electrocardiographic criteria assessed in the present study, all with sensitivity and accuracy higher than 50%, and specificity ranging from 78.5% to 100%, may be attributed to the clinical profile of the study sample, which was comprised of severely ill patients whose LVMI was very high.</p>
      <p>Verdecchia et al<sup>22</sup> studied a new electrocardiographic method for the diagnosis of LVH, the Perugia score from the PIUMA study, and found a 17.8% prevalence of LVH. Using the Cornell voltage, Romhilt-Estes and Sokolow-Lyon voltage criteria, they found a prevalence of LVH of 9.1%, 5.2% and 13%, respectively.</p>
      <p>In our study, in turn, the performance of the Perugia score, used for the first time in CRD patients, was excellent, with sensitivity of 72.3%, specificity of 82.4%, and accuracy of 74%, which can also be explained by the high prevalence of LVH.</p>
      <p>Pearson's correlation demonstrated that only the Sokolow-Lyon voltage criterion did not show a coefficient <underline>&gt;</underline> 0.50 in the general population. Among women, only the Cornell voltage and Cornell product showed coefficients <underline>&gt;</underline> 0.50. This may have resulted from the lower LVMI and lower predominance of the concentric pattern of LVH in women. Calculation of the likelihood ratio, in turn, demonstrated that all electrocardiographic criteria assessed had different and significant degrees of strength for the detection of LVH, perhaps also as a reflex of the severity of the disease in the group studied. However, the combination of the results of Pearson's correlation and likelihood ratio shows that the Cornell product was the most reliable criterion for the detection of LVH in the sample assessed.</p>
      <p>Stewart et al<sup>25</sup> found a positive correlation of QTc interval, QTc dispersion and LVH with the degree of deterioration of the renal function. On the other hand, Covic et al<sup>26</sup> conducted a study including 68 non-diabetic patients with stage-5 CRD and demonstrated that the process of HD prolongs QTc interval, but not QTc dispersion, in patients without manifest heart disease. Conversely, Drighil et al's study<sup>21</sup> of 49 patients with stage-5 CRD demonstrated that QTc dispersion increased, whereas the QTc interval remained stable after HD sessions. In our sample of dialysis patients, the QTc interval remained above the upper normal limit (&gt;440ms) and QTc dispersion was high (normal range between 50-60 ms<sup>27</sup>). This observation may bear clinical relevance in view of the high rate of sudden death among this population. It is important to point out that no correlation was found between QTc and QTc dispersion and LVMI. This lack of correlation suggests that changes in QTc and QTc dispersion are more related to metabolic factors than to LVH itself.</p>
      <p>Finally, we should note that the cut-off point used to define LVH in men and women in the present study was based on echocardiographic studies. It is important to point out that there are studies in the literature that used specimens obtained in autopsies as the gold-standard for correlation<sup>10,28</sup>. However, distortions are more likely to occur in such situations since, depending on the time elapsed and clinical condition of the patient before death, the bias can be relevant. In our midst, Rodrigues et al<sup>29</sup> studied hearts from autopsies of healthy individuals who died of accidental causes and suggested the presence of LVH when the left ventricular mass is higher than 218g or 128 g/m in men and 148 g or 88 g/m in women.</p>
      <p>
        <bold>Study limitations</bold>
      </p>
      <p>Given that this study sample was comprised of severely ill patients whose clinical profile and long time of dialysis already correlate with a high prevalence of LVH, perhaps our findings should not be extrapolated to the general population.</p>
      <p>
        <bold>Conclusion</bold>
      </p>
      <p>ECG is a useful, efficient and highly reproducible method for the diagnosis of LVH in patients with stage-5 CRD undergoing HD. In this population, the Cornell product proved to be the most reliable criterion for the detection of LVH. Despite presenting lower sensitivity than echocardiography, the usefulness of ECG is stressed by its ability to detect electrophysiological changes such as QTc and QTc dispersion, which can be correlated with the high frequency of sudden death among this population.</p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>There were no external funding sources for this study.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This article is part of the thesis of Master submitted by Francisco de Assis Costa, from Universidade Federal de S&#227;o Paulo - Escola Paulista de Medicina.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">El electrocardiograma en el diagn&#243;stico de la hipertrofia ventricular de pacientes con enfermedad renal cr&#243;nica</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>FUNDAMENTO: La hipertrofia ventricular izquierda (HVI) es un factor predictor independiente de riesgo cardiovascular y su caracterizaci&#243;n y prevalencia en la enfermedad renal cr&#243;nica (ERC) carecen de mejor estudio. OBJETIVO: Establecer el diagn&#243;stico de HVI en pacientes con ERC en estadio 5 por seis diferentes criterios electrocardiogr&#225;ficos, correlacion&#225;ndolos al &#237;ndice de masa del ventr&#237;culo izquierdo (IMVI) que se obtuvo mediante el ecocardiograma. M&#201;TODOS: Estudio transversal que incluy&#243; a 100 pacientes (58 varones y 42 mujeres, edad de 46,2 &#177; 14,0 a&#241;os) con ERC de todas las etiolog&#237;as, desde hace al menos 6 meses en hemodi&#225;lisis (HD). Se obtuvieron electrocardiograma (ECG) y ecocardiograma de los pacientes, siempre hasta una hora tras el t&#233;rmino de las sesiones de HD. RESULTADOS: La HVI se detect&#243; en 83 pacientes (83%), de los que 56 (67,4%) presentaban el est&#225;ndar conc&#233;ntrico y 27 (32,6%) el est&#225;ndar exc&#233;ntrico de HVI. Todos los m&#233;todos electrocardiogr&#225;ficos estudiados tuvieron sensibilidad, especificidad y exactitud diagn&#243;sticas superiores al 50%. Mediante la correlaci&#243;n lineal de Pearson con el IMVI, solamente el criterio de Sokolow-Lyon voltaje no present&#243; coeficiente &gt; 0,50. Sin embargo, el c&#225;lculo de la raz&#243;n de verosimilitud evidenci&#243; que el ECG tiene poder discriminatorio para diagn&#243;stico de HVI en la poblaci&#243;n estudiada, con &#233;nfasis para los criterios de Producto de Cornell y Romhilt-Estes. No hubo correlaci&#243;n entre IMVI con el QTc y su dispersi&#243;n. CONCLUSI&#211;N: El ECG es un m&#233;todo &#250;til, eficaz y de alta reproductibilidad en el diagn&#243;stico de HVI de los pacientes en HD. En esa poblaci&#243;n, el criterio de Producto de Cornell fue m&#225;s fiable para la detecci&#243;n de HVI.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Nefropat&#237;as</kwd>
        <kwd>ecocardiograf&#237;a</kwd>
        <kwd>electrocardiograf&#237;a</kwd>
        <kwd>hemodi&#225;lisis</kwd>
        <kwd>hipertrofia ventricular izquierda</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO ORIGINAL</bold>
      </p>
      <p>
        <fn id="top-body3">
          <label>
            <bold>El electrocardiograma en el diagn&#243;stico de la hipertrofia ventricular de pacientes con enfermedad renal cr&#243;nica</bold>
          </label>
          <p>
            <bold>Francisco de Assis Costa<sup>I</sup>; Ivan Romero Rivera<sup>I</sup>; Mirian Lira Castro de Vasconcelos<sup>I</sup>; Andr&#233; Falc&#227;o Pedrosa Costa<sup>I</sup>; Rui Manoel dos Santos P&#243;voa<sup>II</sup>; Maria Tereza Nogueira Bombig<sup>II</sup>; Br&#225;ulio Luna Filho<sup>II</sup>; Valter Correia de Lima<sup>II</sup></bold>
          </p>
        </fn>
      </p>
      <p><sup>I</sup>Universidade Estadual de Ci&#234;ncias da Sa&#250;de de Alagoas-UNCISAL, Macei&#243;, AL</p>
      <p><sup>II</sup>Universidade Federal de S&#227;o Paulo-Escola Paulista de Medicina-UNIFESP-EPM, S&#227;o Paulo, SP, Brasil</p>
      <p>Correspond&#234;ncia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p><bold>FUNDAMENTO: </bold> La hipertrofia ventricular izquierda (HVI) es un factor predictor independiente de riesgo cardiovascular y su caracterizaci&#243;n y prevalencia en la enfermedad renal cr&#243;nica (ERC) carecen de mejor estudio.</p>
      <p><bold>OBJETIVO: </bold> Establecer el diagn&#243;stico de HVI en pacientes con ERC en estadio 5 por seis diferentes criterios electrocardiogr&#225;ficos, correlacion&#225;ndolos al &#237;ndice de masa del ventr&#237;culo izquierdo (IMVI) que se obtuvo mediante el ecocardiograma.</p>
      <p><bold>M&#201;TODOS: </bold> Estudio transversal que incluy&#243; a 100 pacientes (58 varones y 42 mujeres, edad de 46,2 &#177; 14,0 a&#241;os) con ERC de todas las etiolog&#237;as, desde hace al menos 6 meses en hemodi&#225;lisis (HD). Se obtuvieron electrocardiograma (ECG) y ecocardiograma de los pacientes, siempre hasta una hora tras el t&#233;rmino de las sesiones de HD.</p>
      <p><bold>RESULTADOS: </bold> La HVI se detect&#243; en 83 pacientes (83%), de los que 56 (67,4%) presentaban el est&#225;ndar conc&#233;ntrico y 27 (32,6%) el est&#225;ndar exc&#233;ntrico de HVI. Todos los m&#233;todos electrocardiogr&#225;ficos estudiados tuvieron sensibilidad, especificidad y exactitud diagn&#243;sticas superiores al 50%. Mediante la correlaci&#243;n lineal de Pearson con el IMVI, solamente el criterio de Sokolow-Lyon voltaje no present&#243; coeficiente <underline>&gt;</underline> 0,50. Sin embargo, el c&#225;lculo de la raz&#243;n de verosimilitud evidenci&#243; que el ECG tiene poder discriminatorio para diagn&#243;stico de HVI en la poblaci&#243;n estudiada, con &#233;nfasis para los criterios de Producto de Cornell y Romhilt-Estes. No hubo correlaci&#243;n entre IMVI con el QTc y su dispersi&#243;n.</p>
      <p><bold>CONCLUSI&#211;N: </bold> El ECG es un m&#233;todo &#250;til, eficaz y de alta reproductibilidad en el diagn&#243;stico de HVI de los pacientes en HD. En esa poblaci&#243;n, el criterio de Producto de Cornell fue m&#225;s fiable para la detecci&#243;n de HVI.</p>
      <p><bold>Palabras clave: </bold> Nefropat&#237;as, ecocardiograf&#237;a, electrocardiograf&#237;a, hemodi&#225;lisis, hipertrofia ventricular izquierda.</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>La HVI es un predictor independiente de morbimortalidad en la poblaci&#243;n general cuando diagnosticada, tanto por el ECG, como por el ecocardiograma<sup>1,2</sup>.</p>
      <p>Desde las observaciones de vanguardia del <italic>Framingham Heart Study</italic>, diversos estudios epidemiol&#243;gicos destacan la HVI como uno de los m&#225;s importantes factores de riesgo para angina de pecho, infarto de miocardio, insuficiencia cardiaca, accidente cerebrovascular y muerte s&#250;bita<sup>3</sup>.</p>
      <p>En la poblaci&#243;n de pacientes con ERC, en sus diversos estadios, las informaciones disponibles son escasas. El estudio PREVEND analiz&#243;, mediante el criterio electrocardiogr&#225;fico de Producto de Cornell, la presencia de HVI en individuos con disfunci&#243;n renal, definida por tasa de filtraci&#243;n glomerular (TFG) &lt; 60 ml/min/1,73 m<sup>2</sup> o microalbumin&#250;ria, y encontr&#243; prevalencia del 5,3%<sup>4</sup>. No obstante, estudios con ecocardiograma estiman que la prevalencia de HVI est&#233; entre el 40% y el 74% en pacientes con ERC en estadio 5, es decir, aquellos con TFG &lt; 15 ml/min/1,73m<sup>2</sup> o en terapia renal sustitutiva<sup>5</sup>.</p>
      <p>Se puede detectar la HVI por ECG, radiograf&#237;a de t&#243;rax, ecocardiograma y resonancia nuclear magn&#233;tica. Sin embargo, en la pr&#225;ctica cl&#237;nica, el ECG y el ecocardiograma son los m&#225;s utilizados, no solamente por razones de disponibilidad, pero, sobre todo, por la relaci&#243;n pron&#243;stica que prev&#233; claramente un riesgo cardiovascular aumentado cuando se observa la HVI<sup>3</sup>.</p>
      <p>El principal objetivo del presente estudio es establecer el diagn&#243;stico de HVI en pacientes con ERC en estadio 5 por seis diferentes criterios electrocardiogr&#225;ficos, correlacion&#225;ndolos al &#237;ndice de masa del ventr&#237;culo izquierdo (IMVI) que se obtuvo mediante el ecocardiograma.</p>
      <p>
        <bold>M&#233;todos</bold>
      </p>
      <p>
        <bold>Pacientes</bold>
      </p>
      <p>En el per&#237;odo de junio de 2006 a febrero de 2007, se evaluaron, en la Fundaci&#243;n Hospital de la Agro-Industria del Az&#250;car y del Alcohol de Alagoas, a 133 pacientes portadores de ERC en estadio 5, de cualquier etiolog&#237;a (ver <xref ref-type="table" rid="t1-body3">Tabla 1</xref>), cl&#237;nicamente estables, en programa de hemodi&#225;lisis (HD) desde hace seis meses como m&#237;nimo. El Comit&#233; de &#201;tica en Investigaci&#243;n en Seres Humanos de la Universidad Estadual de Ciencias de la Salud de Alagoas aprob&#243; el protocolo de estudio y todos los pacientes firmaron el formulario de consentimiento informado, seg&#250;n los principios de la Declaraci&#243;n de Helsinki. Fueron los siguientes los criterios de exclusi&#243;n de la investigaci&#243;n: antecedente de s&#237;ndrome coronario agudo (independientemente del tiempo) o cr&#243;nica; enfermedad valvular; miocardiopat&#237;a de cualquier origen, detectada por el ecocardiograma transtor&#225;cico; derramen peric&#225;rdico; portadores de marcapaso; bloqueo de rama derecha o izquierda; s&#237;ndromes de pre excitaci&#243;n ventricular y cualquier otro ritmo que no el sinusal. O sea, cualesquier factores que potencialmente pudieran interferir con el an&#225;lisis electrocardiogr&#225;fico de HVI. De los 133 pacientes rastreados, se excluyeron a 33. Entre los 100 pacientes seleccionados, todos fueron entrevistados, cuando se obten&#237;a la medida casual de presi&#243;n arterial, y sometidos a ECG y al ecocardiograma transtor&#225;cico, siempre hasta una hora tras el t&#233;rmino de las sesiones de HD.</p>
      <table-wrap id="t1-body3">
        <graphic xlink:href=""/>
      </table-wrap>
      <p>
        <bold>Electrocardiograma</bold>
      </p>
      <p>El ECG de reposo se realiz&#243; con el paciente en posici&#243;n supina, se obtuvo las 12 derivaciones, con velocidad de registro de 25 mm/s, calibraci&#243;n estandarizada para 1,0 mV/cm (equipo Dixtal, modelo EP3&#174;, Brasil). Los trazados electrocardiogr&#225;ficos se analizaron por un &#250;nico observador, cardi&#243;logo experto, sin ninguna implicaci&#243;n con la realizaci&#243;n de los ecocardiogramas, que ejecut&#243; todas las mediciones manualmente, apunt&#225;ndolas de la manera que sigue a continuaci&#243;n: amplitud (mm) de la onda P; de las ondas R de aV<sub>L</sub>, S de V<sub>3</sub>, S de V<sub>1</sub>, R de V<sub>5</sub> o V<sub>6</sub> ; y mayor onda R y S en el plano horizontal; duraci&#243;n (ms) de la onda P, del complejo QRS, de la activaci&#243;n ventricular, del intervalo QT corregido por la f&#243;rmula de Bazzet (promedio de las 12 derivaciones) y de su dispersi&#243;n (QT m&#225;ximo - QT m&#237;nimo). Se evaluaron asimismo los seis criterios electrocardiogr&#225;ficos para diagn&#243;stico de HVI:</p>
      <p>1) Sokolow-Lyon voltaje (SV<sub>1</sub> + RV<sub>5</sub> o V<sub>6</sub><underline>&gt;</underline> 35 mm)<sup>6</sup>;</p>
      <p>2) Sokolow-Lyon producto (SV<sub>1</sub> + RV<sub>5</sub> o V<sub>6</sub> X duraci&#243;n de QRS <underline>&gt;</underline> 3000 mm.ms para mujeres y <underline>&gt;</underline> 4000 mm.ms para varones)<sup>7</sup>;</p>
      <p>3) Voltaje de Cornell (RaV<sub>L</sub> + SV<sub>3</sub><underline>&gt;</underline> 20 mm para mujeres y <underline>&gt;</underline> 28 mm para varones)<sup>8</sup>;</p>
      <p>4) Producto de Cornell (RaV<sub>L</sub> + SV<sub>3</sub> X duraci&#243;n de QRS, para mujeres adicionar 6 mm, <underline>&gt;</underline> 2440 mm.ms)<sup>9</sup>;</p>
      <p>5) score de puntos de Romhilt-Estes: mayor amplitud de R o S <underline>&gt;</underline> 30 mm en el plano horizontal o <underline>&gt;</underline> 20 mm en el plano frontal o est&#225;ndar <italic>strain</italic> en V<sub>5</sub> o V<sub>6</sub> (si en uso de digital vale s&#243;lo un punto) o crecimiento del atrio izquierdo por &#237;ndice de Morris (tres puntos), eje el&#233;ctrico de &#194;QRS arriba de menos 30 grados (dos puntos), duraci&#243;n de QRS <underline>&gt;</underline> 90 ms en V<sub>5</sub> o V<sub>6</sub> o tiempo de activaci&#243;n ventricular <underline>&gt;</underline> 50 ms en V<sub>5</sub> o V<sub>6</sub> (un punto). Debido a este score, se diagnostica la HVI cuando la suma de puntos es <underline>&gt;</underline> 5<sup>10</sup>;</p>
      <p>6) Puntuaci&#243;n de Perugia: la HVI se diagnostica por la presencia de uno o m&#225;s de los siguientes hallazgos: criterio de Cornell, considerando el l&#237;mite para mujeres <underline>&gt;</underline> 20 mm y para varones <underline>&gt;</underline> 24 mm, score de Romhilt-Estes y est&#225;ndar strain<sup>11</sup>.</p>
      <p>El estudio de reproductibilidad del m&#233;todo se hizo por el mismo observador en ocasiones temporalmente distintas, de modo a no ser capaz de recordar e identificar la primera lectura, y por un observador independiente, con doctorado en Cardiolog&#237;a y gran experiencia en electrocardiograf&#237;a, desde el an&#225;lisis de 30 trazados recolectados de modo aleatorio para la evaluaci&#243;n de las variables Sokolow-Lyon voltaje, Romhilt-Estes e intervalo QT.</p>
      <p>
        <bold>Ecocardiograma</bold>
      </p>
      <p>Los ex&#225;menes se hicieron por dos ecocardiografistas titulados por el Departamento de Ecocardiograf&#237;a de la Sociedad Brasile&#241;a de Cardiolog&#237;a, cumpliendo a rajatabla las normas preconizadas por la Directriz para Indicaciones y Utilizaci&#243;n de la Ecocardiograf&#237;a en la Pr&#225;ctica Cl&#237;nica<sup>12</sup>. Se debe notar que ninguno de estos dos observadores mantuvo cualquier relaci&#243;n con el an&#225;lisis de los trazados de ECG. Se pon&#237;a al paciente en dec&#250;bito lateral izquierdo se utiliz&#243; el ecocardi&#243;grafo modelo Caris&#174; (Esaote-Biom&#233;dica, Italia), equipado con transductor de 2,5 MHz, procedi&#233;ndose a los cortes usuales para obtenci&#243;n de un estudio completo a los modos M, bidimensional y Doppler puls&#225;til; simult&#225;neamente al registro continuo del ECG. Seg&#250;n las recomendaciones de la American Society of Echocardiography/European Association of Echocardiography<sup>13</sup> los espesores del septo interventricular (SIVD) y de la pared posterior del ventr&#237;culo izquierdo (PPVID) se obtuvieron en di&#225;stole, y la masa del VI, en grama, calculada segundo la f&#243;rmula: masa del VI = 0,8 X {1,04 [(SIVD + DDVI + PPVID)<sup>3</sup> - (DDVI)<sup>3</sup>]} + 0,6 g<sup>14</sup>, donde SIVD es el septo interventricular en di&#225;stole, DDVI es el di&#225;metro diast&#243;lico final del VI y PPVID es la pared posterior del VI en di&#225;stole. Se corrigi&#243; la masa del VI para la superficie corp&#243;rea. El diagn&#243;stico ecocardiogr&#225;fico de HVI se firm&#243; cuando el IMVI fue &gt; 88 g/m<sup>2</sup> para mujeres y &gt; 102 g/m<sup>2</sup> para varones<sup>13</sup>. Se calcul&#243;, tambi&#233;n, el espesor relativo de la pared del VI (ERP) por la f&#243;rmula: ERP = 2 X PPVID/DDVI, donde PPVI es la pared posterior del VI en di&#225;stole y DDVI es el di&#225;metro diast&#243;lico final del VI. Con base en el c&#225;lculo de la ERP fue posible establecer los dos est&#225;ndares geom&#233;tricos de HVI: el conc&#233;ntrico, cuando la ERP <underline>&gt;</underline> 0,42, y el exc&#233;ntrico, cuando ERP <underline>&lt;</underline> 0,42<sup>13</sup>. Se evalu&#243; la funci&#243;n sist&#243;lica del VI mediante el porcentaje de acortamiento de la cavidad y por la fracci&#243;n de eyecci&#243;n del VI obtenida por el m&#233;todo de Teicholz. El an&#225;lisis de reproductibilidad del m&#233;todo se hizo por los mismos ecocardiografistas con 30 participantes, buscados de modo aleatorio, que tuvieron la masa del VI calculada por la f&#243;rmula de Devereux<sup>14</sup>. Un observador evaluaba el mismo examen en dos ocasiones temporalmente distintas, de igual manera, como en el an&#225;lisis electrocardiogr&#225;fico. El otro observador realizaba una lectura del examen, sin conocimiento de las lecturas del primero observador.</p>
      <p>
        <bold>Mediciones antropom&#233;tricas</bold>
      </p>
      <p>Se verificaron peso y altura, siempre hasta una hora tras el t&#233;rmino de las sesiones dial&#237;ticas. La superficie corp&#243;rea, en m<sup>2</sup>, se calcul&#243; seg&#250;n la ecuaci&#243;n de Mosteller (0,20247 X peso<sup>0,425</sup> X altura<sup>0,725</sup>)<sup>15</sup>. El &#237;ndice de masa corp&#243;rea se calcul&#243; por la divisi&#243;n del peso (Kg) por el cuadrado de la altura (m).</p>
      <p>
        <bold>An&#225;lisis estad&#237;stico</bold>
      </p>
      <p>Las variables continuas se expresaron en promedio y desviaci&#243;n est&#225;ndar. Las variables categ&#243;ricas se expresaron en porcentaje. La asociaci&#243;n entre el IMVI y las dem&#225;s variables de inter&#233;s se hizo por intermedio del coeficiente de correlaci&#243;n de Pearson. Para este estudio, se consider&#243; relevante solamente el coeficiente de Pearson <underline>&gt;</underline> 0,50. Se utiliz&#243; la curva ROC para estudio de la sensibilidad, especificidad y exactitud de los seis criterios electrocardiogr&#225;ficos investigados, a excepci&#243;n de la puntuaci&#243;n de Perugia (variable categ&#243;rica). La prueba exacta de Fisher se utiliz&#243; para la comparaci&#243;n de las sensibilidades de los m&#233;todos electrocardiogr&#225;ficos evaluados, de acuerdo con los est&#225;ndares geom&#233;tricos de HVI, y se utiliz&#243; la prueba t de Student para el cotejo entre el IMVI de varones y mujeres. La raz&#243;n de verosimilitud (l<italic>ikelihood ratio</italic>) para los criterios electrocardiogr&#225;ficos tambi&#233;n se calcul&#243;, utiliz&#225;ndose para ello el coeficiente de concordancia de Lin. Para verificarse la significancia estad&#237;stica, en todas las comparaciones, se tuvieron en cuenta los intervalos de confianza del 95% y p &lt; 0,05.</p>
      <p>
        <bold>Resultados</bold>
      </p>
      <p>De los 100 pacientes que completaron el estudio, 58 eran varones (58%) y 42 eran mujeres (42%), con edad de 46,2 &#177; 14,0 a&#241;os (variaci&#243;n de 18 a 78 a&#241;os) y tiempo de HD de 50,7 &#177; 46,5 meses (variaci&#243;n de seis a 225 meses, mediana de 33,5 meses). La <xref ref-type="table" rid="t2-body3">Tabla 2</xref> resume los datos demogr&#225;ficos y las caracter&#237;sticas cl&#237;nicas de los pacientes y la <xref ref-type="table" rid="t3-body3">Tabla 3</xref> re&#250;ne los hallazgos electrocardiogr&#225;ficos.</p>
      <table-wrap id="t2-body3">
        <graphic xlink:href=""/>
      </table-wrap>
      <table-wrap id="t3-body3">
        <graphic xlink:href=""/>
      </table-wrap>
      <p>La prevalencia de HVI por el ecocardiograma fue del 83%, siendo que 56 de estos pacientes (67,4%) presentaban el tipo conc&#233;ntrico y 27 (32,6%) pacientes ten&#237;an el est&#225;ndar exc&#233;ntrico de HVI. El IMVI en la poblaci&#243;n estudiada fue de 154,9 &#177; 57,3 g/m<sup>2</sup>. Separado por sexo, el IMVI fue de 159,9 &#177; 57,0 g/m<sup>2</sup> en los varones y de 148,0 &#177; 57,6 g/m<sup>2</sup> en las mujeres (p = 0,306). La <xref ref-type="table" rid="t4-body3">Tabla 4</xref> evidencia los valores de las variables ecocardiogr&#225;ficas estudiadas.</p>
      <table-wrap id="t4-body3">
        <graphic xlink:href=""/>
      </table-wrap>
      <p>Se llev&#243; a cabo el estudio de la sensibilidad, la especificidad y la exactitud de los seis criterios electrocardiogr&#225;ficos evaluados en la poblaci&#243;n general, seg&#250;n est&#225; detallado en la <xref ref-type="table" rid="t5-body3">Tabla 5</xref>. Las sensibilidades, las especificidades y los valores de p, de acuerdo con los est&#225;ndares geom&#233;tricos de HVI en la poblaci&#243;n general (HVI conc&#233;ntrica: IMVI = 178,2 &#177; 54,8 g/m<sup>2</sup> y HVI exc&#233;ntrica: IMVI = 152,0 &#177; 38,2 g/m<sup>2</sup> - p = 0,028), est&#225;n detalladas en la <xref ref-type="table" rid="t6-body3">Tabla 6</xref>. Entre los 17 (17%) pacientes que no presentaban HVI, el IMVI fue de 82,9 &#177; 13,6 g/m<sup>2</sup>.</p>
      <p content-type="asset">
        <table-wrap id="t5-body3">
          <graphic xlink:href=""/>
        </table-wrap>
      </p>
      <p content-type="asset">
        <table-wrap id="t6-body3">
          <graphic xlink:href=""/>
        </table-wrap>
      </p>
      <p>Para las variables continuas criterios de voltaje de Sokolow-Lyon, producto de Sokolow-Lyon, voltaje de Cornell, producto de Cornell y Romhilt-Estes, fueron las siguientes &#225;reas bajo las curvas ROC: 0,85; 0,85; 0,85; 0,83 y 0,80, respectivamente.</p>
      <p>Al procederse a la correlaci&#243;n de Pearson para variables continuas, se observ&#243; un coeficiente <underline>&gt;</underline> 0,50 entre el IMVI y las siguientes variables en la poblaci&#243;n general: criterios de producto de Sokolow-Lyon, voltaje de Cornell, producto de Cornell y Romhilt-Estes. Cuando se divide por sexo, la correlaci&#243;n de Pearson fue <underline>&gt;</underline> 0,50 entre el IMVI y todos los criterios electrocardiogr&#225;ficos evaluados, incluso el QTc en la poblaci&#243;n masculina. Entre las mujeres, la correlaci&#243;n result&#243; <underline>&gt;</underline> 0,50 solamente entre el IMVI y los criterios de voltaje de Cornell y producto de Cornell. Por ser la puntuaci&#243;n de Perugia una variable categ&#243;rica, no se puede efectuar la correlaci&#243;n de Pearson con el IMVI. Vea <xref ref-type="table" rid="t7-body3">Tabla 7</xref>.</p>
      <p content-type="asset">
        <table-wrap id="t7-body3">
          <graphic xlink:href=""/>
        </table-wrap>
      </p>
      <p>Seg&#250;n se puede notar en la <xref ref-type="table" rid="t8-body3">Tabla 8</xref>, el c&#225;lculo de la raz&#243;n de verosimilitud evidencia que todos los m&#233;todos electrocardiogr&#225;ficos evaluados presentan el poder discriminatorio del ECG en el diagn&#243;stico de HVI en la poblaci&#243;n estudiada, con destaque para los criterios de producto de Cornell y Romhilt-Estes.</p>
      <table-wrap id="t8-body3">
        <graphic xlink:href=""/>
      </table-wrap>
      <p>En cuanto al estudio de la reproductibilidad, el nivel de concordancia intraobservador para las variables electrocardiogr&#225;ficas de criterios de voltaje de Sokolow-Lyon, Romhilt-Estes e intervalo QT fue de 0,99; 0,97 y 0,96, respectivamente. La concordancia interobservador para las mismas variables fue de 0,99; 0,79 y 0,94, respectivamente. Para la variable masa del VI, obtenida por el ecocardiograma, el nivel de concordancia intra e interobservador fue de 0,97 y 0,98, respectivamente.</p>
      <p>
        <bold>Discusi&#243;n</bold>
      </p>
      <p>La HVI generalmente conlleva un incremento de la amplitud del complejo QRS, con consecuente desviaci&#243;n de orientaci&#243;n para la izquierda y posterior de las fuerzas el&#233;ctricas, de eso originando ondas S profundas en las derivaciones precordiales derechas. Por otro lado, la mayor activaci&#243;n ventricular transversa, resultado de la HVI, ocasiona el incremento en la duraci&#243;n del QRS y de la deflexi&#243;n intrinsecoide (intervalo entre el inicio de la inscripci&#243;n y el punto m&#225;ximo del complejo QRS en las derivaciones precordiales izquierdas)<sup>3,17</sup>.</p>
      <p>Indiscutiblemente, el ECG es un examen complementario menos sensible del que el ecocardiograma transtor&#225;cico en la detecci&#243;n de la HVI. Sin embargo, cuando se diagnostica el proceso mediante aquel m&#233;todo proped&#233;utico, termina con pron&#243;stico severo, con comprobado incremento de la morbimortalidad cardiovascular. Seg&#250;n con lo que se mencion&#243; anteriormente, son mayores los riesgos de angina de pecho, infarto de miocardio, accidente cerebrovascular, insuficiencia cardiaca y muerte s&#250;bita<sup>17</sup>.</p>
      <p>El estudio de <italic>Framingham</italic>, en f<italic>ollow-up</italic> de 30 a&#241;os, detall&#243; de manera clara que el ECG con est&#225;ndar de HVI aumentaba la raz&#243;n de riesgo de eventos coronarios de 3,0 a 5,8 veces; los de accidente cerebrovascular de 3,2 a 7,0 veces y los de insuficiencia cardiaca en hasta 17,5 veces. Particularmente en relaci&#243;n con la insuficiencia cardiaca, la posibilidad de desarrollarla fue la mayor en la presencia de un ECG compatible con HVI que aun de una cardiomegalia observada a la radiograf&#237;a de t&#243;rax<sup>18</sup>.</p>
      <p>As manifestaciones de HVI al ECG relacionadas a alteraciones de la repolarizaci&#243;n ventricular del tipo <italic>strain</italic> (infradesnivel del segmento ST con convexidad para cima, asociado a una inversi&#243;n asim&#233;trica de la onda T en las derivaciones precordiales y perif&#233;ricas izquierdas) parecen se&#241;alar tanto hacia para la presencia de HVI, como de isquemia mioc&#225;rdica. Ese est&#225;ndar, seg&#250;n el estudio de <italic>Framingham</italic>, aumentaba el riesgo de complicaciones cardiovasculares en 5,8 veces en varones y en 2,4 veces en mujeres<sup>17</sup>. En el estudio LIFE, el est&#225;ndar <italic>strain</italic> al ECG, observado en 971 pacientes, entre los 8.854 evaluados en cinco anos, aument&#243; la mortalidad cardiovascular en 2,2 veces, el riesgo de infarto de miocardio en 2,1 veces y el de accidente cerebrovascular en 1,7 vez<sup>19</sup>.</p>
      <p>Al tener en cuenta que el ECG es un examen de bajo costo y es de una excelente reproductibilidad, a pesar de sus conocidas limitaciones en cuanto a su sensibilidad diagn&#243;stica, el est&#225; siendo ampliamente utilizado en estudios poblacionales que evaluaron la prevalencia de HVI, su regresi&#243;n o mantenimiento con intervenci&#243;n farmacol&#243;gica, sobre todo en pacientes hipertensos<sup>20-22</sup>.</p>
      <p>Por otra parte, no se puede dejar de tomar en consideraci&#243;n que la mayor&#237;a de los criterios electrocardiogr&#225;ficos para la detecci&#243;n de HVI se valid&#243; en poblaciones con alta prevalencia de enfermedades cardiovasculares. La consecuencia obvia es la baja <italic>performance</italic> de esos criterios cuando aplicados en muestras con baja prevalencia de dichas enfermedades.</p>
      <p>Cabe se&#241;alar que no hab&#237;a el predominio macizo de un sexo respecto al otro en la muestra estudiada, cuyos individuos eran, en un promedio, j&#243;venes (edad de 46,2 &#177; 14,0 a&#241;os), con IMC normal (promedio de 22,7 &#177; 3,7 Kg/m<sup>2</sup>) y hab&#237;a solamente cuatro tabaquistas (4%). Esta excepci&#243;n es importante para enmarcar a la poblaci&#243;n del estudio, seg&#250;n los cuatro factores que interfieren m&#225;s con el diagn&#243;stico electrocardiogr&#225;fico de la HVI: sexo (sensibilidad mayor en los hombres); edad (la sensibilidad aumenta entre los adultos mayores); peso (sensibilidad menor en los obesos) y tabaquismo (sensibilidad menor en los fumadores)<sup>23</sup>.</p>
      <p>Alfakih et al.<sup>24</sup>, en un estudio que implic&#243; a 288 pacientes hipertensos, evaluaron cuatro de los m&#233;todos electrocardiogr&#225;ficos aqu&#237; investigados, encontrando cifras de sensibilidad y especificidad para los criterios de voltaje de Sokolow-Lyon, producto de Sokolow-Lyon, voltaje de Cornell y producto de Cornell del 28,7% y el 92,1%; el 36,8% y el 91,4%; el 21,3% y el 94,8%; el 31,1% y el 91,4%, respectivamente. El mejor desempe&#241;o verificado por los seis criterios electrocardiogr&#225;ficos aqu&#237; evaluados se puede asignar al perfil cl&#237;nico de la muestra estudiada, conformada por pacientes severos, cuyo IMVI fue muy elevado.</p>
      <p>Verdecchia et al.<sup>22</sup>, estudiando un nuevo m&#233;todo electrocardiogr&#225;fico para diagn&#243;stico de HVI, la puntuaci&#243;n de Perugia, del estudio de PIUMA, encontraron una prevalencia del 17,8% de HVI. En el mismo estudio, la prevalencia de HVI por los criterios de voltaje de Cornell, Romhilt-Estes y voltaje de Sokolow-Lyon fue del 9,1%, el 5,2% y el 13%, respectivamente.</p>
      <p>Sin embargo, en el presente estudio, la <italic>performance</italic> de la puntuaci&#243;n de Perugia, por la primera vez probado en pacientes con ERC, fue excelente, con sensibilidad del 72,3%, especificidad del 82,4% y exactitud del 74%, lo que tambi&#233;n se puede explicar mediante la alta prevalencia de HVI.</p>
      <p>El c&#225;lculo de la raz&#243;n de verosimilitud evidencia que todos los criterios electrocardiogr&#225;ficos evaluados presentan grados variados y expresivos de fuerza en la detecci&#243;n de la HVI, quiz&#225; tambi&#233;n un reflejo de la severidad del grupo estudiado. Sin embargo, la combinaci&#243;n de los resultados de la correlaci&#243;n de Pearson y de la raz&#243;n de verosimilitud revela que el criterio de producto de Cornell fue el m&#225;s fiable en la detecci&#243;n de HVI en la muestra evaluada.</p>
      <p>Stewart et al.<sup>25</sup> encontraron correlaci&#243;n positiva entre intervalo QTc, dispersi&#243;n del QTc y HVI con el grado de deterioro de la funci&#243;n renal. Por otro lado, Covic et al.<sup>26</sup>, en estudio que incluy&#243; a 68 pacientes con ERC en estadio 5, no-diab&#233;ticos, revelaron que el proceso de HD prolonga el intervalo QTc, pero no su dispersi&#243;n, en pacientes sin enfermedad cardiaca manifiesta. En la muestra aqu&#237; estudiada, de pacientes en di&#225;lisis, el intervalo QTc se mantuvo superior al l&#237;mite superior de la normalidad ( &gt; 440 ms) y la dispersi&#243;n del QTc se elev&#243; (normal entre 50-60 ms<sup>27</sup>). Esta observaci&#243;n puede tener relevancia cl&#237;nica ante la alta tasa de muerte s&#250;bita en esta poblaci&#243;n. Es importante notar que no hubo correlaci&#243;n del QTc y dispersi&#243;n del QTc con el IMVI. Esta falta de correlaci&#243;n sugiere que las alteraciones del QTc y de su dispersi&#243;n est&#233;n relacionadas m&#225;s a factores metab&#243;licos que propiamente a la HVI.</p>
      <p>Finalmente, queda el registro de que el punto de corte para establecerse la HVI en varones y mujeres, en este estudio, tuvo como base trabajos ecocardiogr&#225;ficos. Se debe se&#241;alar que hay en la literatura estudios que utilizaron la pieza que se obtuvo en la necropsia como patr&#243;n-oro de correlaci&#243;n<sup>10,28</sup>. Adem&#225;s, en estas condiciones, son mayores las posibilidades de distorsiones, una vez que, dependiendo del tiempo y del estado cl&#237;nico del paciente antes de la ocurrencia del &#243;bito, el sesgo puede ser relevante. En nuestro medio, Rodrigues et al.<sup>29</sup>, estudiando corazones bajo necropsia de individuos sanos, v&#237;ctimas de muerte accidental, sugieren presencia de HVI cuando la masa ventricular izquierda es superior a 218 &#243; 128 g/m en varones y 148 &#243; 88 g/m en mujeres.</p>
      <p>
        <bold>Limitaciones del estudio</bold>
      </p>
      <p>Por tratarse de una muestra compuesta de pacientes severos, cuyo perfil cl&#237;nico y elevado tiempo en di&#225;lisis ya apuntan hacia una alta prevalencia de HVI, tal vez no se puedan extrapolar los resultados aqu&#237; presentados a la poblaci&#243;n general.</p>
      <p>
        <bold>Conclusi&#243;n</bold>
      </p>
      <p>El ECG es un m&#233;todo &#250;til, eficaz y de alta reproductibilidad en el diagn&#243;stico de HVI de los pacientes con ERC en estadio 5, en HD. En esa poblaci&#243;n, el criterio de producto de Cornell fue m&#225;s fiable en la detecci&#243;n de HVI. Aunque se presente una menor sensibilidad que el ecocardiograma, la capacidad de detectar alteraciones electrofisiol&#243;gicas -como el QTc y su dispersi&#243;n, que pueden correlacionarse con la elevada ocurrencia de muerte s&#250;bita en esta poblaci&#243;n- realza la utilidad del ECG.</p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiaci&#243;n</bold>
      </p>
      <p>El presente estudio no tuvo fuentes de financiaci&#243;n externas.</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>Este art&#237;culo forma parte de tesis de Maestr&#237;a de Francisco de Assis Costa, por la Universidad Federal de S&#227;o Paulo - Escuela Paulista de Medicina.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
</article>
